# EDGAR Filing Document

**Accession Number:** 0000103145
**File Stem:** 0001104659-26-055672
**Filing Date:** 2026-5
**Character Count:** 163580
**Document Hash:** 889f4e65efcb89204fa7cbf2cdc8b805
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-055672.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001104659-26-055672

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 79

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VEECO INSTRUMENTS INC
- **CENTRAL INDEX KEY:** 0000103145
- **STANDARD INDUSTRIAL CLASSIFICATION:** SPECIAL INDUSTRY MACHINERY, NEC [3559]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 112989601
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-16244
- **FILM NUMBER:** 26943803

**BUSINESS ADDRESS:**
- **STREET 1:** TERMINAL DRIVE
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803
- **BUSINESS PHONE:** 516 677-0200

**MAIL ADDRESS:**
- **STREET 1:** TERMINAL DRIVE
- **CITY:** PLAINVIEW
- **STATE:** NY
- **ZIP:** 11803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VACUUM ELECTRONIC MANUFACTURING CORP
- **DATE OF NAME CHANGE:** 19700408

?xml version='1.0' encoding='ASCII'? VEECO INSTRUMENTS INC._March 31, 2026

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended March 31, 2026**

**OR**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission file number 0-16244**

**VEECO INSTRUMENTS INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Delaware** | **11-2989601** |
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |
| **Terminal DrivePlainview, New York** | **11803** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code:

**(516) 677-0200**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.01 per share** | **VECO** | **The NASDAQ Global Select Market** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes ☒ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;Large accelerated filer ☒ | &nbsp;&nbsp;Accelerated filer ☐ |
| &nbsp;&nbsp;Non-accelerated filer ☐ | &nbsp;&nbsp;Smaller reporting company ☐ |
|  | &nbsp;&nbsp;Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 30, 2026, there were 61,033,485 shares of the registrant's common stock outstanding.

------

[**Table of Contents**](#TOC)

**VEECO INSTRUMENTS INC.**

**INDEX**

---

| | |
|:---|:---|
| [Safe Harbor Statement](#SafeHarborStatement_940941) | 1 |
| [PART I—FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_642777) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1. Financial Statements](#Item1FinancialStatements_377663) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF) | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 3. Quantitative and Qualitative Disclosures about Market Risk](#Item3QuantitativeandQualitativeDisclosur) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 4. Controls and Procedures](#Item4ControlsandProcedures_183959) | 31 |
| [PART II—OTHER INFORMATION](#PARTIIOTHERINFORMATION_174374) | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1. Legal Proceedings](#Item1LegalProceedings_321234) | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 1A. Risk Factors](#Item1ARiskFactors) | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities) | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 3. Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_376506) | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 4. Mine Safety Disclosures](#Item4MineSafetyDisclosures_741021) | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 5. Other Information](#Item5OtherInformation_241196) | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;[Item 6. Exhibits](#Item6Exhibits_919397) | 32 |
| [SIGNATURES](#SIGNATURES_882826) | 33 |

---

[**Table of Contents**](#TOC)

**Safe Harbor Statement**

This quarterly report on Form 10-Q (the "Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, relating to Veeco Instruments Inc. (together with its consolidated subsidiaries, "Veeco," the "Company," "Registrant," "we," "our," or "us," unless the context indicates otherwise) that are based on management's expectations, estimates, projections, and assumptions. When used in this Report, the words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates," and variations of these words and similar expressions are intended to identify forward-looking statements. Discussions containing such forward-looking statements may be found in Part I - Items 1, 2, and 3 hereof, as well as within this Report generally.

In addition, the preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates and assumptions are based on knowledge of current events and planned actions to be undertaken in the future, they may ultimately differ from actual results. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. All estimates and assumptions are subject to a number of risks and uncertainties that could cause actual results to differ materially from these estimates and assumptions.

Forward-looking statements in this discussion include, but are not limited to, those regarding anticipated growth and trends in our business and markets, including trends related to artificial intelligence and high-performance computing, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for the current and future periods, and other statements that are not historical facts. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation, those set forth under the heading "Risk Factors" in Part 1, Item 1A of our 2025 Form 10-K, and the following:

● Unfavorable market conditions;

● Risks associated with operating a global business;

● Changes in trade policies, export controls, and the ongoing trade dispute between the U.S. and China;

● An inability to obtain required export licenses for the sale of our products;

● Risks associated with uncertainties related to changes in global trade policies, global trade disputes, and increased tariffs;

● The timing of our orders, shipments, and revenue recognition;

● Significant third party competition;

● Risks associated with operating in industries characterized by rapid technological change;

● Risks associated with use of artificial intelligence by us and by our competitors, including operational risks, the unintended release of proprietary information, compliance costs, privacy concerns, risks related to intellectual property rights, and risks related to AI's impact on the workforce;

● Our dependency on the demand for consumer electronic products and automobiles;

● Our concentrated customer base;

● The cyclicality of the industries we serve;

[**Table of Contents**](#TOC)

● A failure to estimate customer demand accurately;

● Our reliance on a limited number of suppliers, some of whom are our sole source for particular components;

● A failure to successfully manage our outsourcing activities or a failure of our outsourcing partners to perform as anticipated;

● Our long and unpredictable sales cycles;

● Customer order cancellations or modifications;

● Risks associated with business combinations, acquisitions, strategic investments and divestitures;

● Risks associated with global regulatory requirements;

● Disruptions in our information technology systems or data security incidents, including risks associated with increasingly sophisticated cybersecurity attacks;

● An inability to effectively enforce and protect our intellectual property rights;

● Claims of intellectual property infringement by others;

● Tightening credit markets;

● Foreign currency exchange risks;

● Asset impairment charges;

● Changes in accounting pronouncements or taxation rules, practices, or rates;

● Restrictions, covenants and repurchase provisions appearing in our current debt facilities;

● Possible impairment to our ability to utilize our research and development credits carryforwards caused by the issuance of common stock upon the conversion of the Notes (as defined herein);

● Delays in or failure to complete the Merger (as defined herein), whether due to an inability by either party to satisfy one or more conditions to closing, including an inability to obtain certain required regulatory approvals, the occurrence of events or changes in circumstances that give rise to the termination of the Merger Agreement (as defined herein) by either party, or otherwise;

● Risks related to the pendency of the Merger and its effect on our business, financial condition, results of operations, cash flows and stock price;

● Value our stockholders will receive due to fluctuation of Axcelis' common stock market price;

● Delaware law not entitling stockholders to an appraisal of the fair value of their shares;

● Our stockholders having a reduced ownership and voting rights in the combined company;

● Risks associated with an adverse judgement challenging the Merger;

● Significant costs in connection with the Merger and integration of the two companies;

[**Table of Contents**](#TOC)

● Limited ability to pursue alternatives to the Merger;

● Diversion of management time and attention from ordinary course business operations to the Merger and other potential disruptions to our business relating thereto;

● Volatility of our common share price ;

● Inability to attract, retain, and motivate employees could have a material adverse effect;

● Risks associated with non-compliance with environmental, health, and safety regulations;

● Environmental, social and governance goals, strategies and requirements which could be costly to implement and which expose us to risks associated with failures to comply;

● Measures adopted by Veeco which may have anti-takeover effects or which may make an acquisition of our Company by another company more difficult; and

● Other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q, and 8-K, and from time-to-time in our other SEC reports.

All forward-looking statements speak only to management's expectations, estimates, projections and assumptions as of the date of this filing or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this filing.

[**Table of Contents**](#TOC)

**PART I**—**FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Balance Sheets**

(in thousands, except share amounts)

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,** <br>**2025** |
| **Assets** | (unaudited) |  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $179535 | $163466 |
| &nbsp;&nbsp;Short-term investments | 203796 | 226763 |
| &nbsp;&nbsp;Accounts receivable, net | 150521 | 110685 |
| &nbsp;&nbsp;Contract assets | 21723 | 34838 |
| &nbsp;&nbsp;Inventories | 282231 | 275298 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 35613 | 34286 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 873419 | 845336 |
| Property, plant, and equipment, net | 107817 | 108646 |
| Operating lease right-of-use assets | 24084 | 24606 |
| Intangible assets, net | 4991 | 5696 |
| Goodwill | 214964 | 214964 |
| Deferred income taxes | 124141 | 122935 |
| Other assets | 3553 | 3612 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $1352969 | $1325795 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable | $60153 | $55344 |
| &nbsp;&nbsp;Accrued expenses and other current liabilities | 52038 | 45503 |
| &nbsp;&nbsp;Contract liabilities | 92731 | 74161 |
| &nbsp;&nbsp;Income taxes payable | 1763 | 3048 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 206685 | 178056 |
| Deferred income taxes | 513 | 532 |
| Long-term debt | 226253 | 226009 |
| Long-term operating lease liabilities | 31140 | 31837 |
| Other liabilities | 4716 | 3852 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | 469307 | 440286 |
| Stockholders' equity: |  |  |
| Preferred stock, $0.01 par value; 500,000 shares authorized; no shares issued and outstanding. |  |  |
| Common stock, $0.01 par value; 120,000,000 shares authorized; 61,032,453 shares issued and outstanding at March 31, 2026 and 60,388,539 shares issued and outstanding at December 31, 2025 | 610 | 604 |
| Additional paid-in capital | 1305119 | 1306176 |
| Accumulated deficit | (423389) | (423065) |
| Accumulated other comprehensive income | 1322 | 1794 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity** | 883662 | 885509 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and stockholders' equity** | $1352969 | $1325795 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Statements of Operations**

(in thousands, except per share amounts)

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2025** |
| Net sales  | $158341 | $167292 |
| Cost of sales | 102513 | 98825 |
| Gross profit | 55828 | 68467 |
| Operating expenses, net: |  |  |
| &nbsp;&nbsp;Research and development | 29875 | 28514 |
| &nbsp;&nbsp;Selling, general, and administrative | 26016 | 25028 |
| &nbsp;&nbsp;Amortization of intangible assets | 705 | 821 |
| &nbsp;&nbsp;Merger costs | 2012 |  |
| &nbsp;&nbsp;Other operating expense (income), net | (122) | (44) |
| Total operating expenses, net | 58486 | 54319 |
| Operating income (loss) | (2658) | 14148 |
| &nbsp;&nbsp;Interest income | 3276 | 3342 |
| &nbsp;&nbsp;Interest expense | (2101) | (2506) |
| Income (loss) before income taxes | (1483) | 14984 |
| &nbsp;&nbsp;Income tax expense (benefit) | (1159) | 3037 |
| Net income (loss) | $(324) | $11947 |
| Income (loss) per common share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.01) | $0.21 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted  | $(0.01) | $0.20 |
| Weighted average number of shares: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 60414 | 57753 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 60414 | 60234 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Statements of Comprehensive Income (Loss)**

(in thousands)

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2025** |
| Net income (loss) | $(324) | $11947 |
| Other comprehensive income (loss), net of tax: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on available-for-sale securities | (472) | 100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in currency translation adjustments |  | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss), net of tax | (472) | 108 |
| Total comprehensive income (loss) | $(796) | $12055 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Veeco Instruments Inc. and Subsidiaries**

**Consolidated Statements of Cash Flows**

(in thousands)

(unaudited)

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2025** |
| **Cash Flows from Operating Activities** |  |  |
| Net income (loss) | $(324) | $11947 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 5037 | 5035 |
| &nbsp;&nbsp;Non-cash interest expense | 244 | 257 |
| &nbsp;&nbsp;Deferred income taxes | (1088) | 1567 |
| &nbsp;&nbsp;Share-based compensation expense | 8511 | 9208 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;Accounts receivable and contract assets | (26721) | (14011) |
| &nbsp;&nbsp;Inventories  | (6933) | (7316) |
| &nbsp;&nbsp;Prepaid expenses and other current assets | (859) | (2434) |
| &nbsp;&nbsp;Accounts payable and accrued expenses | 12519 | 21874 |
| &nbsp;&nbsp;Contract liabilities | 18570 | (7776) |
| &nbsp;&nbsp;Income taxes receivable and payable, net | (1269) | 2475 |
| &nbsp;&nbsp;Other, net | 248 | (834) |
| Net cash provided by (used in) operating activities | 7935 | 19992 |
| **Cash Flows from Investing Activities** |  |  |
| Capital expenditures | (5103) | (6755) |
| Proceeds from the sale of investments | 35640 | 66200 |
| Payments for purchases of investments | (12846) | (44922) |
| Net cash provided by (used in) investing activities | 17691 | 14523 |
| **Cash Flows from Financing Activities** |  |  |
| Restricted stock tax withholdings | (11041) | (6675) |
| Proceeds (net of tax withholdings) from option exercises and employee stock purchase plan | 1483 | 1399 |
| Net cash provided by (used in) financing activities | (9558) | (5276) |
| Effect of exchange rate changes on cash and cash equivalents | 1 | 9 |
| Net increase (decrease) in cash and cash equivalents | 16069 | 29248 |
| Cash and cash equivalents - beginning of period | 163466 | 145819 |
| Cash and cash equivalents - end of period | $179535 | $175067 |
| **Supplemental Disclosure of Cash Flow Information** |  |  |
| &nbsp;&nbsp;Interest paid | $143 | $712 |
| &nbsp;&nbsp;Income taxes paid, net of refunds received | 714 | (1671) |
| **Non-cash activities** |  |  |
| &nbsp;&nbsp;Capital expenditures included in accounts payable and accrued expenses | 857 | 2455 |
| &nbsp;&nbsp;Right-of-use assets obtained in exchange for lease obligations |  | 127 |

---

See accompanying Notes to the Consolidated Financial Statements*.*

[**Table of Contents**](#TOC)

**Note 1 — Basis of Presentation**

The accompanying unaudited Consolidated Financial Statements of Veeco have been prepared in accordance with U.S. GAAP as defined in Financial Accounting Standards Board ("FASB") Accounting Standards Codification 270 for interim financial information and with the instructions to Rule 10-01 of Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements as the interim information is an update of the information that was presented in Veeco's most recent annual financial statements. For further information, refer to Veeco's Consolidated Financial Statements and Notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal, recurring nature.

Veeco reports interim quarters on a 13-week basis ending on the last Sunday of each quarter. The fourth quarter always ends on the last day of the calendar year, December 31. The 2026 interim quarters end on March 29, June 28, and September 27, and the 2025 interim quarters end on March 30, June 29, and September 28. These interim quarters are reported as March 31, June 30, and September 30 in Veeco's interim consolidated financial statements.

The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on management's knowledge of current events and actions it may undertake in the future, actual results may differ from these estimates.

*Recent Accounting Standards Not Yet Adopted*

In November 2024, the FASB issued ASU 2024-03, "Disaggregation of Income Statements Expenses (Subtopic 220-40)," to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement's expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.

*Pending Merger with Axcelis Technologies, Inc.*

On September 30, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Axcelis Technologies, Inc., a Delaware corporation ("Axcelis"), and Victory Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Axcelis ("Merger Sub"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub will merge with and into Veeco (the "Merger"), with Veeco surviving as a wholly-owned subsidiary of Axcelis. See Note 10 *Merger* for additional information.

[**Table of Contents**](#TOC)

**Note 2 — Income Per Common Share**

Basic income per share is calculated by dividing net income by the weighted average number of shares outstanding during the period. Diluted income per share is calculated by dividing net income available to common shareholders by the weighted average number of shares used to calculate basic income per share plus the weighted average number of common share equivalents outstanding during the period. The dilutive effect of outstanding options to purchase common stock and share-based awards is considered in diluted income per share by application of the treasury stock method. The dilutive effect of performance share units is included in diluted income per common share if the performance targets have been achieved, or would have been achieved if the reporting date was the end of the contingency period. Finally, the Company includes the dilutive effect of shares issuable upon conversion of its Notes in the calculation of diluted income per share using the if-converted method. The Company must settle the principal amount of the 2029 Notes in cash, and has the option to settle any excess of the conversion value over the principal amount in any combination of cash or shares. As such, the Company only includes the excess shares that may be issuable above the principal amount of the 2029 Notes in the dilutive share count, if the effect would be dilutive.

The computations of basic and diluted income per share for the three months ended March 31, 2026 and 2025 are as follows:

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands, except per share amounts)* | *(in thousands, except per share amounts)* |
| **Numerator:**  |  |  |
| Net income (loss) | $(324) | $11947 |
| Interest expense associated with convertible notes |  | 253 |
| Net income (loss) available to common shareholders | $(324) | $12200 |
| **Denominator:** |  |  |
| Basic weighted average shares outstanding | 60414 | 57753 |
| Effect of potentially dilutive share-based awards |  | 693 |
| Dilutive effect of convertible notes  |  | 1788 |
| Diluted weighted average shares outstanding | 60414 | 60234 |
| **Net income (loss) per common share:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.01) | $0.21 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.01) | $0.20 |
| Potentially dilutive shares excluded from the diluted calculation as their effect would be antidilutive | 232 | 954 |
| Maximum potential shares to be issued for settlement of convertible senior notes excluded from the diluted calculation as their effect would be antidilutive | N/A | 174 |

---

**Note 3 — Assets**

*Investments*

Short-term investments are generally classified as available-for-sale and reported at fair value, with unrealized gains and losses, net of tax, presented as a separate component of stockholders' equity under the caption "Accumulated other comprehensive income" in the Consolidated Balance Sheets. These securities may include U.S. treasuries, government agency securities, corporate debt, and commercial paper, all with maturities of greater than three months when purchased. All realized gains and losses and unrealized losses resulting from declines in fair value that are other than temporary are included in "Other operating expense (income), net" in the Consolidated Statements of Operations.

[**Table of Contents**](#TOC)

Fair value is the price that would be received for an asset or the amount paid to transfer a liability in an orderly transaction between market participants. Veeco classifies certain assets based on the following fair value hierarchy:

Level 1: Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly; and

Level 3: Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Veeco has evaluated the estimated fair value of financial instruments using available market information and valuations as provided by third-party sources. The use of different market assumptions or estimation methodologies could have a significant effect on the estimated fair value amounts.

The following table presents the portion of Veeco's assets that were measured at fair value on a recurring basis at March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **March 31, 2026** |  |  |  |  |
| &nbsp;&nbsp;**Cash equivalents** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Certificate of deposits and time deposits | $76124 | $— | $— | $76124 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market cash | 20174 |  |  | 20174 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $96298 | $— | $— | $96298 |
| &nbsp;&nbsp;**Short-term investments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasuries | $65522 | $— | $— | $65522 |
| &nbsp;&nbsp;&nbsp;&nbsp;Government agency securities |  | 52653 |  | 52653 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 85621 |  | 85621 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $65522 | $138274 | $— | $203796 |
| **December 31, 2025** |  |  |  |  |
| &nbsp;&nbsp;**Cash equivalents** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Certificate of deposits and time deposits | $63893 | $— | $— | $63893 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market cash | 15327 |  |  | 15327 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $79220 | $— | $— | $79220 |
| &nbsp;&nbsp;**Short-term investments** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasuries | $77110 | $— | $— | $77110 |
| &nbsp;&nbsp;&nbsp;&nbsp;Government agency securities |  | 53488 |  | 53488 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 96165 |  | 96165 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $77110 | $149653 | $— | $226763 |

---

There were no transfers between fair value measurement levels during the three months ended March 31, 2026.

[**Table of Contents**](#TOC)

At March 31, 2026 and December 31, 2025, the amortized cost and fair value of available-for-sale securities consist of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | <br>**Amortized**<br>**Cost** | **Gross**<br>**Unrealized**<br>**Gains** | **Gross**<br>**Unrealized**<br>**Losses** | <br>**Estimated**<br>**Fair Value** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **March 31, 2026** |  |  |  |  |
| &nbsp;&nbsp;U.S. treasuries | $65743 | $11 | $(232) | $65522 |
| &nbsp;&nbsp;Government agency securities | 52784 | 15 | (146) | 52653 |
| &nbsp;&nbsp;Corporate debt | 85839 | 9 | (227) | 85621 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total**  | $204366 | $35 | $(605) | $203796 |
| **December 31, 2025** |  |  |  |  |
| &nbsp;&nbsp;U.S. treasuries | $77106 | $52 | $(48) | $77110 |
| &nbsp;&nbsp;Government agency securities | 53473 | 50 | (35) | 53488 |
| &nbsp;&nbsp;Corporate debt | 96144 | 86 | (65) | 96165 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $226723 | $188 | $(148) | $226763 |

---

Available-for-sale securities in a loss position at March 31, 2026 and December 31, 2025 consist of:

---

| | | |
|:---|:---|:---|
|  | **Continuous Loss Position**  | **Continuous Loss Position**  |
|  | **for Less than 12 Months** | **for Less than 12 Months** |
|  | <br>**Estimated**<br>**Fair Value** | **Gross**<br>**Unrealized**<br>**Losses** |
|  | *(in thousands)* | *(in thousands)* |
| **March 31, 2026** |  |  |
| U.S. treasuries | $44358 | $(232) |
| Government agency securities | 42772 | (146) |
| Corporate debt | 70790 | (227) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $157920 | $(605) |
| **December 31, 2025** |  |  |
| U.S. treasuries | $37609 | $(48) |
| Government agency securities | 24028 | (35) |
| Corporate debt | 45675 | (65) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $107312 | $(148) |

---

The contractual maturities of securities classified as available-for-sale at March 31, 2026 were as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** |
|  | **Amortized**<br>**Cost** | **Estimated**<br>**Fair Value** |
|  | *(in thousands)* | *(in thousands)* |
| Due in one year or less | $131982 | $131876 |
| Due after one year through two years | 70488 | 70051 |
| Due after two years through three years | 1896 | 1869 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $204366 | $203796 |

---

Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. There were no realized gains or losses, or unrealized losses from declines in fair value that are other than temporary, for the three months ended March 31, 2026 and 2025.

[**Table of Contents**](#TOC)

*Accounts Receivable*

Accounts receivable is presented net of an allowance for doubtful accounts of $1.0 million at March 31, 2026 and December 31, 2025. The Company considers its current expectations of future economic conditions when estimating its allowance for doubtful accounts.

*Inventories*

Inventories at March 31, 2026 and December 31, 2025 consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,**  | **December 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Materials | $158494 | $156385 |
| Work-in-process | 87244 | 80947 |
| Finished goods | 7976 | 7017 |
| Evaluation inventory | 28517 | 30949 |
| &nbsp;&nbsp;**Total** | $282231 | $275298 |

---

*Prepaid Expenses and Other Current Assets*

Prepaid expenses and other current assets primarily consist of supplier deposits, prepaid value-added tax, lease deposits, prepaid insurance, prepaid software and maintenance, and other receivables. The Company had deposits with its suppliers of $9.8 million for both March 31, 2026 and December 31, 2025, respectively.

*Property, Plant, and Equipment*

Property, plant, and equipment at March 31, 2026 and December 31, 2025 consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,**  | **December 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Land | $5061 | $5061 |
| Building and improvements | 61776 | 61749 |
| Machinery and equipment <sup>(1)</sup> | 202303 | 198898 |
| Leasehold improvements | 55246 | 55210 |
| &nbsp;&nbsp;Gross property, plant, and equipment | 324386 | 320918 |
| Less: accumulated depreciation and amortization | 216569 | 212272 |
| &nbsp;&nbsp;**Property, plant, and equipment, net** | $107817 | $108646 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Machinery and equipment also includes software, furniture, and fixtures

For the three months ended March 31, 2026 and 2025, depreciation expense was $4.3 million and $4.2 million, respectively.

*Goodwill*

Goodwill represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and separately recognized. There were no changes to goodwill during the three months ended March 31, 2026.

*Intangible Assets*

Intangible assets consist of purchased technology, customer relationships, patents, trademarks and tradenames, licenses, and backlog, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined.

[**Table of Contents**](#TOC)

The components of purchased intangible assets were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
|  | <br>**Gross**<br>**Carrying**<br>**Amount** | **Accumulated**<br>**Amortization**<br>**and**<br>**Impairment** | <br>**Net** <br>**Amount** | <br>**Gross**<br>**Carrying**<br>**Amount** | **Accumulated**<br>**Amortization**<br>**and**<br>**Impairment** | <br>**Net**<br>**Amount** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| Technology | $355928 | $355731 | $197 | $355928 | $355437 | $491 |
| Customer relationships | 146925 | 142131 | 4794 | 146925 | 141720 | 5205 |
| Trademarks and tradenames | 30910 | 30910 |  | 30910 | 30910 |  |
| Other | 3746 | 3746 |  | 3746 | 3746 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $537509 | $532518 | $4991 | $537509 | $531813 | $5696 |

---

Other intangible assets primarily consist of patents, licenses, and backlog.

**Note 4 — Liabilities**

*Accrued Expenses and Other Current Liabilities*

The components of accrued expenses and other current liabilities at March 31, 2026 and December 31, 2025 consist of:

---

| | | |
|:---|:---|:---|
|  | **March 31,**  | **December 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Payroll and related benefits | $24698 | $21772 |
| Warranty | 10596 | 10348 |
| Operating lease liabilities | 4100 | 4164 |
| Interest | 2328 | 680 |
| Professional fees | 1367 | 1315 |
| Sales, use, and other taxes | 2395 | 958 |
| Merger costs | 871 | 727 |
| Contingent consideration | 275 | 275 |
| Other | 5408 | 5264 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $52038 | $45503 |

---

*Warranty*

Warranties are typically valid for one year from the date of system final acceptance. The Company estimates the costs that may be incurred under the warranty which are determined by analyzing specific product and historical configuration statistics and regional warranty support costs and are affected by product failure rates, material usage, and labor costs incurred in correcting product failures during the warranty period. Unforeseen component failures or exceptional component performance can also result in changes to warranty costs. Changes in product warranty reserves for the three months ended March 31, 2026 include:

---

| | |
|:---|:---|
|  | **March 31,**  |
|  | **2026** |
|  | *(in thousands)* |
| **Balance - beginning of the year** | $10348 |
| &nbsp;&nbsp;Warranties issued | 1781 |
| &nbsp;&nbsp;Consumption of reserves | (1319) |
| &nbsp;&nbsp;Changes in estimate | (214) |
| **Balance - March 31, 2026** | $10596 |

---

[**Table of Contents**](#TOC)

*Contract Liabilities and Performance Obligations*

Contract liabilities consist of unsatisfied performance obligations related to advanced payments received and billing in excess of revenue recognized. The contract liability balance as of December 31, 2025 was approximately $74.2 million, of which the Company recognized approximately $20.3 million in revenue during the three months ended March 31, 2026.

This reduction in contract liabilities was offset in part by new billings for products and services which were unsatisfied performance obligations to customers and revenue had not yet been recognized as of March 31, 2026.

As of March 31, 2026, the Company has approximately $142.8 million of remaining performance obligations on contracts with an original estimated duration of one year or more, of which approximately 51% is expected to be recognized within one year, with the remaining amounts expected to be recognized between one to three years. The Company has elected to exclude disclosures regarding remaining performance obligations that have an original expected duration of one year or less.

*Convertible Senior Notes*

*2025 Notes*

On November 17, 2020, as part of the privately negotiated exchange agreement, the Company issued $132.5 million of 3.50% convertible senior notes due 2025 (the "2025 Notes"). The 2025 Notes bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 15 and July 15 of each year, commencing on July 15, 2021. On May 19, 2023, in connection with the completion of a private offering of $230.0 million aggregate principal amount of 2.875% convertible senior notes due 2029 described below, the Company repurchased and retired approximately $106.0 million in aggregate principal amount of its outstanding 2025 Notes. The remaining principal amount of $26.5 million 2025 Notes matured on January 15, 2025 and were settled through the issuance of 1.1 million shares of the Company's common stock to the noteholders.

*2027 Notes*

On May 18, 2020, the Company completed a private offering of $125.0 million of 3.75% convertible senior notes due 2027 (the "2027 Notes"). The Company received net proceeds of approximately $121.9 million, after deducting underwriting discounts and fees and expenses payable by the Company. Additionally, the Company used approximately $10.3 million of cash to purchase capped calls, discussed below. The 2027 Notes bore interest at a rate of 3.75% per year, payable semiannually in arrears on June 1 and December 1 of each year, commencing on December 1, 2020. The 2027 Notes were scheduled to mature on June 1, 2027, unless earlier purchased by the Company, redeemed, or converted. On May 19, 2023, in connection with the completion of a private offering of $230.0 million aggregate principal amount of 2.875% convertible senior notes due 2029 described below, the Company repurchased and retired approximately $100.0 million in aggregate principal amount of its outstanding 2027 Notes. The remaining principal amount of $25.0 million 2027 Notes were settled on May 15, 2025 in a private transaction with all remaining 2027 Note holders for 1.6 million shares of the Company's common stock and $5.4 million in cash. The settlement was accounted for as an induced conversion resulting in an inducement expense of approximately $0.7 million and a decrease to additional paid-in capital of $20.2 million on the Consolidated Balance Sheets.

*2029 Notes*

On May 19, 2023, the Company completed a private offering of $230.0 million of 2.875% convertible senior notes due 2029 (the "2029 Notes"). The Company received net proceeds of approximately $223.2 million, after deducting underwriting discounts and fees and expenses payable by the Company. Additionally, the Company used approximately $198.8 million of net proceeds from the offering to fund the cash portion of the 2025 Notes and 2027 Notes extinguishments described above and the remainder for general corporate purposes. The 2029 Notes bear interest at a rate of 2.875% per year, payable semiannually in arrears on June 1 and December 1 of each year, commencing on December 1, 2023. The 2029 Notes mature on June 1, 2029, unless earlier purchased by the Company, redeemed, or

[**Table of Contents**](#TOC)

converted. The Company will settle any conversions of the 2029 Notes by paying cash up to the aggregate principal amount of the 2029 Notes to be converted, and paying or delivering either cash, shares of Company's common stock, or a combination of cash and shares of common stock at the Company's election, in respect of the remainder, if any, of the conversion obligation in excess of the aggregate principal amount of the 2029 Notes being converted.

The 2029 Notes are unsecured senior obligations of Veeco and rank senior in right of payment to any of Veeco's subordinated indebtedness; equal in right of payment to all of Veeco's unsecured indebtedness that is not subordinated; effectively subordinated in right of payment to any of Veeco's secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally subordinated to all indebtedness and other liabilities (including trade payables) of Veeco's subsidiaries.

The Company may redeem for cash, at its option, all or any portion of the outstanding 2029 Notes at any time on or after June 8, 2026, at a redemption price equal to 100% of the principal amount of such 2029 Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date, if the last reported sale price of the common stock has been at least 130% of the conversion price for the applicable series of 2029 Notes then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides the redemption notice. Upon the Company's notice of redemption, holders may elect to convert their 2029 Notes based on the conversion rates and criteria outlined below.

The 2029 Notes are convertible at the option of the holders upon the satisfaction of specified conditions and during certain periods as described below. The initial conversion rate is 34.21852 shares of the Company's common stock per $1,000 principal amount, representing an initial effective conversion price of $29.22 per share of common stock. The conversion rate may be subject to adjustment upon the occurrence of certain specified events.

Holders may convert all or any portion of their 2029 Notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding February 1, 2029, only under the following circumstances:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) During any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) During the five consecutive business day period after any five consecutive trading day period (the "measurement period") in which the trading price per one thousand dollar principal amount of 2029 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Veeco's common stock and the conversion rate on each such trading day;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If the Company calls any or all of applicable series of the 2029 Notes for redemption at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Upon the occurrence of specified corporate events.

Holders may convert their 2029 Notes at any time, regardless of the foregoing circumstances, on February 1, 2029, until the close of business on the business day immediately preceding the maturity date.

The 2025, 2027, and 2029 Notes were recorded as a single unit within liabilities in the consolidated balance sheets as the conversion features within the Notes were not derivatives that require bifurcation and the Notes did not involve a substantial premium. Transaction costs of $1.9 million, $3.1 million, and $6.8 million incurred in connection with the issuance of the 2025 Notes, 2027 Notes, and 2029 Notes, respectively, were recorded as direct deductions from the related debt liabilities and recognized as non-cash interest expense using the effective interest method over the expected terms of the Notes.

[**Table of Contents**](#TOC)

The carrying value of the 2029 Notes is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
|  | **Principal Amount** | **Unamortized transaction costs** | **Net carrying value** | **Principal Amount** | **Unamortized transaction costs** | **Net carrying value** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| 2029 Notes | $230000 | $(3747) | $226253 | $230000 | $(3991) | $226009 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net carrying value** | $230000 | $(3747) | $226253 | $230000 | $(3991) | $226009 |

---

Total interest expense related to the 2025 Notes, 2027 Notes, and 2029 Notes is as follows:

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Cash Interest Expense |  |  |
| &nbsp;&nbsp;Coupon interest expense - 2025 Notes | $— | $39 |
| &nbsp;&nbsp;Coupon interest expense - 2027 Notes |  | 234 |
| &nbsp;&nbsp;Coupon interest expense - 2029 Notes | 1653 | 1653 |
| Non-cash Interest Expense |  |  |
| &nbsp;&nbsp;Amortization of debt discount/transaction costs- 2025 Notes |  | 4 |
| &nbsp;&nbsp;Amortization of debt discount/transaction costs- 2027 Notes |  | 18 |
| &nbsp;&nbsp;Amortization of debt discount/transaction costs- 2029 Notes | 244 | 235 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Interest Expense** | $1897 | $2183 |

---

The Company determined the 2029 Notes are Level 2 liabilities in the fair value hierarchy and had an estimated fair value at March 31, 2026 of $328.4 million.

*Capped Call Transactions*

In connection with the offering of the 2027 Notes, on May 13, 2020, the Company entered into privately negotiated capped call transactions (the "Capped Call Transactions"), pursuant to capped call confirmations, covering the initial underlying shares of the 2027 Notes of approximately 8.9 million shares, for an aggregate premium of $10.3 million. The Capped Call Transactions feature a $13.98 exercise price and a capped price of approximately $18.46 per share, and mature on June 1, 2027. The Capped Call Transactions are subject to certain adjustments under the terms of the capped call confirmations.

The Capped Call Transactions are separate transactions entered into by the Company with the capped call counterparties, are not part of the terms of the 2027 Notes and did not change the previous holders' rights under the 2027 Notes. Previous holders of the 2027 Notes did not have any rights with respect to the Capped Call Transactions. The cost of the Capped Call Transactions is not expected to be tax-deductible as the Company did not elect to integrate the Capped Call Transactions into the 2027 Notes for tax purposes. The Company used a portion of the net proceeds from the offering of the 2027 Notes to pay for the Capped Call Transactions, and the cost of the Capped Call Transactions was recorded as a reduction of the Company's additional paid-in capital in the accompanying consolidated financial statements.

*Revolving Credit Facility* 

On December 16, 2021, the Company entered into a Loan and Security Agreement (the "Loan and Security Agreement") providing for a senior secured revolving credit facility in an aggregate principal amount of $150 million including a $15 million letter of credit sublimit. The Loan and Security Agreement was subsequently amended to increase the aggregate principal amount to $225 million on August 2, 2024 (the "Third Amendment"), and $250 million on June 16, 2025 (the "Fourth Amendment"). On September 30, 2025, the Loan and Security Agreement was subsequently amended to make certain amendments to the definition of "Changes of Control" and "Merger, Consolidation and Sale of Assets" covenant in the Loan and Security Agreement following the announcement of the Company's Merger Agreement with Axcelis (the "Fifth Amendment") (as amended to date, the "Credit Facility"). The Credit Facility matures on June 16, 2030,

[**Table of Contents**](#TOC)

subject to a springing maturity date of March 2, 2029 upon the occurrence of certain liquidity events described in the Fourth Amendment. The Credit Facility is guaranteed by the Company's direct material U.S. subsidiaries, subject to customary exceptions. Borrowings under the Credit Facility are secured by a first-priority lien on substantially all of the assets of the Company, subject to customary exceptions. Subject to certain conditions and the receipt of commitments from the lenders, the Loan and Security Agreement allows for revolving commitments under the Credit Facility to be increased by up to $100 million, with additional amounts available so long as the Secured Net Leverage Ratio (as defined in the Loan and Security Agreement) does not exceed 2.50 to 1.00. The existing lenders under the Credit Facility, are entitled, but not obligated, to provide such incremental commitments.

Borrowings will bear interest at a floating rate which can be, at the Company's option based on certain conditions in the Loan and Security Agreement, either (a) an alternate base rate plus an applicable rate ranging from 0.25% to 1.00% or (b) a Secured Overnight Financing Rate ("SOFR") (with a floor of 0.00%) for the specified interest period plus an applicable rate ranging from 1.25% to 2.00%, in each case, depending on the Company's Secured Net Leverage Ratio (as defined in the Loan and Security Agreement). The Company will pay an unused commitment fee ranging from 0.20% to 0.30% based on unused capacity under the Credit Facility and the Company's Secured Net Leverage Ratio. The Company may use the proceeds of borrowings under the Credit Facility to pay transaction fees and expenses, provide for its working capital needs and reimburse drawings under letters of credit and for other general corporate purposes.

The Loan and Security Agreement, contains customary affirmative covenants for transactions of this type, including, among others, the provision of financial and other information to the administrative agent, notice to the administrative agent upon the occurrence of certain material events, preservation of existence, maintenance of properties and insurance, compliance with laws, including environmental laws, the provision of additional guarantees, and an affiliate transactions covenant, subject to certain exceptions. The Loan and Security Agreement, contains customary negative covenants, including, among others, restrictions on the ability to merge and consolidate with other companies, incur indebtedness, refinance our existing convertible notes, grant liens or security interests on assets, make investments, acquisitions, loans, or advances, pay dividends, and sell or otherwise transfer assets.

The Loan and Security Agreement, contains financial maintenance covenants that require the Borrower to maintain an Interest Coverage Ratio (as defined in the Loan and Security Agreement) of not less than 3.00 to 1.00, a Total Net Leverage Ratio (as defined in the Loan and Security Agreement) of not more than 4.50 to 1.00, and a Secured Net Leverage Ratio (as defined in the Loan and Security Agreement) of not more than 3.00 to 1.00, in each case, tested at the end of each fiscal quarter. The Loan and Security Agreement, also provides for a number of customary events of default, including, among others: payment defaults to the lenders; voluntary and involuntary bankruptcy proceedings; covenant defaults; material inaccuracies of representations and warranties; certain change of control events; material money judgments; and other customary events of default. The occurrence of an event of default could result in the acceleration of obligations and the termination of lending commitments under the Loan and Security Agreement.

No amounts were outstanding under the Credit Facility as of March 31, 2026 or December 31, 2025.

*Other Liabilities*

Other Liabilities at March 31, 2026 and December 31, 2025 was approximately $4.7 million and $3.9 million, respectively, which included merger costs, medical and dental benefits for former executives, asset retirement obligations, and tax liabilities.

**Note 5 — Commitments and Contingencies**

*Leases*

The Company's operating leases primarily include real estate leases for properties used for manufacturing, R&D activities, sales and service, and administration, as well as certain equipment leases. Some leases may include options to renew for a period of up to 5 years, while others may include options to terminate the lease. The weighted average

[**Table of Contents**](#TOC)

remaining lease term of the Company's operating leases as of March 31, 2026 was 10 years, and the weighted average discount rate used in determining the present value of future lease payments was 5.7%.

The following table provides the maturities of lease liabilities at March 31, 2026:

---

| | |
|:---|:---|
|  | **Operating**<br>**Leases** |
|  | *(in thousands)* |
| **Payments due by period:** |  |
| 2026 | $3211 |
| 2027 | 4938 |
| 2028 | 4481 |
| 2029 | 4313 |
| 2030 | 4077 |
| Thereafter | 26539 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total future minimum lease payments | 47559 |
| Less: Imputed interest | (12319) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $35240 |
| **Reported as of March 31, 2026** |  |
| Accrued expenses and other current liabilities | $4100 |
| Long-term operating lease liabilities | 31140 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $35240 |

---

Operating lease costs for both the three months ended March 31, 2026 and 2025 was $1.2 million. Variable lease costs for the three months ended March 31, 2026 and 2025 were $0.2 million and $0.3 million, respectively. Additionally, the Company has an immaterial amount of short-term leases. Cash outflows from operating leases for the three months ended March 31, 2026 and 2025 were $2.1 million and $1.8 million, respectively.

*Receivable Purchase Agreement*

The Company entered into a receivable purchase agreement with a financial institution to sell certain of its trade receivables from customers without recourse, up to $30.0 million at any point in time. Pursuant to this agreement, the Company sold no receivables for the three months ended March 31, 2026, and $30.0 million was available under the agreement for additional sales of receivables as of March 31, 2026. The Company sold no receivables for the three months ended March 31, 2025. The net sale of accounts receivable under the agreement is reflected as a reduction of accounts receivable in the Company's Consolidated Balance Sheet at the time of sale and any fees for the sale of trade receivables were not material for the periods presented.

*Purchase Commitments*

Veeco has purchase commitments of $205.8 million at March 31, 2026 to secure the rights to various assets and services to be used in the future in the normal course of business, substantially all of which become due within one year.

*Bank Guarantees*

Veeco has bank guarantees and letters of credit issued by a financial institution on its behalf as needed. At March 31, 2026, outstanding bank guarantees and standby letters of credit totaled $5.1 million, and unused bank guarantees and letters of credit of $37.2 million were available to be drawn upon.

[**Table of Contents**](#TOC)

*Legal Proceedings*

The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.

*Tariffs*

On February 20, 2026, the U.S. Supreme Court issued a decision invalidating tariffs imposed under the International Emergency Economic Powers Act. The Company is continuing to evaluate the impact of these developments on its business and financial statements, and has initiated various processes and procedures to file claims for refunds for these previously paid duties. However, as the tariff landscape continues to shift and evolve, there remains uncertainty as to the amount that will ultimately be refunded, the Company's ability to collect such refunds, and the timing of such refunds, and as such, the Company has not recorded any adjustments to its financial statements related to these potential refunds. While the Company continues to implement measures to mitigate tariff-related cost pressures, these actions may not fully offset increased costs in future periods.

**Note 6 — Equity**

*Statement of Stockholders' Equity*

The following tables present the changes in Stockholders' Equity:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | <br>**Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated** <br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income** | <br>**Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **Balance at December 31, 2025** | 60389 | $604 | $1306176 | $(423065) | $1794 | $885509 |
| Net income (loss) |  |  |  | (324) |  | (324) |
| Other comprehensive income (loss), net of tax |  |  |  |  | (472) | (472) |
| Share-based compensation expense |  |  | 8511 |  |  | 8511 |
| Net issuance under employee stock plans | 643 | 6 | (9568) |  |  | (9562) |
| **Balance at March 31, 2026** | 61032 | $610 | $1305119 | $(423389) | $1322 | $883662 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | <br>**Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated** <br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income** | <br>**Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **Balance at December 31, 2024** | 56828 | $569 | $1227134 | $(458455) | $1522 | $770770 |
| Net income |  |  |  | 11947 |  | 11947 |
| Other comprehensive income (loss), net of tax |  |  |  |  | 108 | 108 |
| Share-based compensation expense |  |  | 9208 |  |  | 9208 |
| Settlement of the 2025 Notes | 1104 | 11 | 26489 |  |  | 26500 |
| Net issuance under employee stock plans | 360 | 3 | (6678) |  |  | (6675) |
| **Balance at March 31, 2025** | 58292 | $583 | $1256153 | $(446508) | $1630 | $811858 |

---

[**Table of Contents**](#TOC)

*Accumulated Other Comprehensive Income ("AOCI")*

The following table presents the changes in the balances of each component of AOCI, net of tax:

---

| | | | |
|:---|:---|:---|:---|
|  | <br><br>**Foreign**<br>**Currency**<br>**Translation** | **Unrealized**<br>**Gains (Losses)**<br>**on Available-**<br>**for-Sale** <br>**Securities** | <br>**Total** |
|  | *(in thousands)* | *(in thousands)* | *(in thousands)* |
| **Balance - December 31, 2025** | $1855 | $(61) | $1794 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) |  | (472) | (472) |
| **Balance - March 31, 2026** | $1855 | $(533) | $1322 |

---

There were immaterial reclassifications from AOCI into net income for the three months ended March 31, 2026 and 2025.

**Note 7 — Share-based Compensation**

Restricted share awards are issued to employees and to members of our board of directors that are subject to specified restrictions and a risk of forfeiture. The restrictions typically lapse over one to four years and may entitle holders to dividends and voting rights. Other types of share-based compensation include performance share awards, performance share units, and restricted share units (collectively with restricted share awards, "restricted shares"), as well as options to purchase common stock.

Share-based compensation expense was recognized in the following line items in the Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Cost of sales | $1511 | $1343 |
| Research and development | 2506 | 3048 |
| Selling, general, and administrative | 4494 | 4817 |
| &nbsp;&nbsp;**Total** | $8511 | $9208 |

---

For the three months ended March 31, 2026, equity activity related to non-vested restricted shares and performance shares was as follows:

---

| | | |
|:---|:---|:---|
|  | <br>**Number of**<br>**Shares** | **Weighted**<br>**Average**<br>**Grant Date**<br>**Fair Value** |
|  | *(in thousands)* |  |
| **Balance - December 31, 2025** | 2551 | $28.89 |
| &nbsp;&nbsp;Granted | 1113 | 30.79 |
| &nbsp;&nbsp;Performance award adjustments | 117 | 32.25 |
| &nbsp;&nbsp;Vested | (942) | 27.70 |
| &nbsp;&nbsp;Forfeited | (32) | 23.41 |
| **Balance - March 31, 2026** | 2807 | $30.25 |

---

**Note 8 — Income Taxes**

Income taxes are estimated for each of the jurisdictions in which the Company operates. Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, as well as the tax effect of carryforwards. Realization of net deferred tax assets is dependent on future taxable income.

[**Table of Contents**](#TOC)

At the end of each interim reporting period, the effective tax rate is aligned with expectations for the full year. This estimate is used to determine the income tax provision on a year-to-date basis and may change in subsequent interim periods.

Income before income taxes and income tax expense for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2026** | **2025** | **2025** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Income (loss) before income taxes | $| (1483) | $| 14984 |
| Income tax expense (benefit) | $ | (1159) | $ | 3037 |
| Effective tax rate |  | 78.15% |  | 20.27% |

---

The Company's income tax benefit for the three months ended March 31, 2026 was $1.2 million, compared to an income tax expense of $3.0 million for the comparable prior period.

For the three months ended March 31, 2026, the effective tax rate was higher than the U.S. statutory tax rate primarily related to a discrete income tax benefit for share-based compensation windfall. For the three months ended March 31, 2025, the effective tax rate was in line with the U.S. statutory tax rate, which included a $1.5 million tax expense related to share-based compensation shortfalls, partially offset by tax benefits related to Foreign-Derived Intangible Income and research and development tax credits.

**Note 9 — Segment Reporting and Geographic Information**

The Company operates and measures its results in one operating segment and therefore has one reportable segment: the development, manufacture, sales, and support of semiconductor and thin film process equipment primarily sold to make electronic devices. The accounting policies of this one operating segment are the same as those described in the Company's 2025 Form 10-K. The Chief Operating Decision Maker ("CODM"), the Chief Executive Officer, assesses segment performance and decides how to allocate resources based on net income that is reported on the Consolidated Statements of Operations. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets. The Company does not have intra-entity sales or transfers. The CODM uses net income to evaluate income generated from segment assets (return on assets) in deciding whether to reinvest profits into the segment or into other parts of the Company, such as for acquisitions. Net income is used to monitor forecast versus actual results. The CODM also uses net income in competitive analysis by benchmarking the Company's competitors. The competitive analysis along with the monitoring of forecasted versus actual results are used in assessing performance of the segment. The Company regularly provides management reports to the CODM on a consolidated expense basis which includes actuals, forecasted, and budgeted information. These reports are similar to the Company's consolidated financial statements.

There are no additional expenses categories and amounts that meet the definition of significant expense items that are regularly provided to the CODM and included in the reported measure of net income.

Veeco serves the following four end-markets:

*Semiconductor*

The Semiconductor market refers to early process steps in logic and memory applications where silicon wafers are processed. There are many different process steps in forming patterned wafers, such as deposition, etching, masking, and doping, where the microchips are created but remain on the silicon wafer. This market includes mask blank production for extreme ultraviolet ("EUV") lithography, as well as Advanced Packaging, which refers to a portfolio of wafer-level assembly technologies that enable improved performance of electronic products, such as smartphones, high-end servers, and graphical processors.

[**Table of Contents**](#TOC)

*Compound Semiconductor*

The Compound Semiconductor market includes Photonics, Power Electronics, RF Filters and Amplifiers, and Solar applications. Photonics refers to light source technologies and laser-based solutions for 3D sensing, datacom and telecom applications. This includes micro-LED, laser diodes, edge emitting lasers and vertical cavity surface emitting lasers ("VCSELs"). Power Electronics refers to semiconductor devices such as rectifiers, inverters and converters for the control and conversion of electric power in applications such as fast or wireless charging of consumer electronics and automotive applications. RF power amplifiers and filters (including surface acoustic wave ("SAW") and bulk acoustic wave ("BAW") filters) are used in 5G communications infrastructure, smartphones, tablets, and mobile devices. They make use of radio waves for wireless broadcasting and/or communications. Solar refers to power obtained by harnessing the energy of the sun through the use of compound semiconductor devices such as photovoltaics.

*Data Storage* 

Data Storage refers to the Hard Disk Drive ("HDD") market, for which our systems enable customers to manufacture thin film magnetic heads for hard disk drives as part of large capacity storage applications.

*Scientific & Other*

Scientific & Other refers to advanced materials research and a range of manufacturing applications including optical coatings (laser mirrors, optical filters, and anti-reflective coatings).

Sales by end-market and geographic region for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,**  | **Three months ended March 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| **Sales by end-market** |  |  |
| &nbsp;&nbsp;Semiconductor | $109042 | $123823 |
| &nbsp;&nbsp;Compound Semiconductor | 18808 | 14397 |
| &nbsp;&nbsp;Data Storage | 10213 | 6705 |
| &nbsp;&nbsp;Scientific & Other | 20278 | 22367 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $158341 | $167292 |
| **Sales by geographic region** |  |  |
| &nbsp;&nbsp;United States | $32225 | $24062 |
| &nbsp;&nbsp;EMEA<sup>(1)</sup> | 15784 | 12337 |
| &nbsp;&nbsp;China | 19956 | 70892 |
| &nbsp;&nbsp;Rest of APAC | 90364 | 59976 |
| &nbsp;&nbsp;Rest of World | 12 | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $158341 | $167292 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) EMEA consists of Europe, the Middle East, and Africa

For geographic reporting, sales are attributed to the location in which the customer facility is located.

**Note 10 — Merger**

*Merger Agreement with Axcelis Technologies, Inc.*

On September 30, 2025, the Company entered into Merger Agreement with Axcelis, and Merger Sub. Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub will merge with and into Veeco, with Veeco surviving as a wholly-owned subsidiary of Axcelis. The Merger Agreement was approved by Veeco's board of directors (except for one (1) independent director who serves on the Axcelis board of directors as well and thus recused himself) and, on February 6, 2026, by the stockholders of each company. The completion of the Merger remains subject to the satisfaction or (to the extent permissible) waiver of customary closing

[**Table of Contents**](#TOC)

conditions, including the final pending regulatory approval from the State Administration for Market Regulation of the People's Republic of China, and is currently expected to close in the second half of 2026.

Under the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company common stock issued and outstanding immediately prior to the Effective Time (other than shares owned by Axcelis, the Company, Merger Sub, or their wholly-owned subsidiaries) will be converted into the right to receive 0.3575 newly issued shares of Axcelis common stock (the "Axcelis Common Stock"). No fractional shares of Axcelis will be issued in the Merger, and the Company stockholders will receive cash in lieu of fractional shares as part of the merger consideration. Following the Merger, Axcelis' common stockholders are expected to own approximately 58.4% of the shares of Axcelis Common Stock on a fully diluted basis, and the Company's common stockholders will own approximately 41.6%.

The Merger Agreement contains customary representations, warranties, and covenants, including restrictions on the conduct of business prior to closing and provisions regarding the treatment of the Company's outstanding equity awards and employee benefits. The Merger Agreement may be terminated under certain circumstances, including by mutual consent of the Company and Axcelis or if the Merger is not consummated by September 30, 2026 (subject to automatic extensions until as late as June 30, 2027 under certain conditions with respect to the receipt of regulatory approvals).

If the board of directors of either party makes an Adverse Recommendation Change, as defined in the Merger Agreement, the other party shall have the right to terminate the Merger Agreement, and the non-terminating party will be required to pay the other party the following termination fee: (i) if the non-terminating party is Axcelis, a termination fee of $108,700,000; and (ii) if the non-terminating party is Veeco, a termination fee of $77,500,000. Each party may also be required to pay such termination fee if such party enters into a competing proposal within twelve months of termination of the Merger Agreement under certain circumstances. In addition, if the Merger Agreement is terminated by a party due to the other party's breach of the Merger Agreement that would result in a failure of an applicable closing condition (subject to the applicable cure period set forth in the Merger Agreement), then the non-terminating party will be required to pay a fixed expense reimbursement amount of $15,000,000.

The Company incurred an additional $2.0 million in legal, accounting, consulting fees and employee-related costs in connection with the proposed Merger during the three months ended March 31, 2026, included within "Merger costs" on the Consolidated Statement of Operations.

Additional information regarding the Merger Agreement and the proposed Merger is included in the Company's Current Report on Form 8-K filed with the SEC on October 1, 2025.

[**Table of Contents**](#TOC)

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Cautionary Statement Regarding Forward Looking Statements**

Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to facilitate an understanding of our business and results of operations. This MD&A should be read in conjunction with our Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements included elsewhere in this Form 10-Q. The following discussion contains forward-looking statements and should also be read in conjunction with the cautionary statement set forth at the beginning of this Form 10-Q.

The following section generally discusses 2026 and 2025 items and year-to-year comparisons between 2026 and 2025. Discussions of 2025 items that are not included in this Form 10-Q can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2 of our Quarterly Report on Form 10-Q for the interim period ended March 31, 2025, filed on May 7, 2025.

**Executive Summary**

We are an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, and single wafer wet processing technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco's systems and service offerings, visit www.veeco.com.

**Merger with Axcelis Technologies, Inc.**

On September 30, 2025, we entered into an Agreement and Plan of Merger (the "Merger Agreement") with Axcelis Technologies, Inc., a Delaware corporation ("Axcelis"), and Victory Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Axcelis ("Merger Sub"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub shall be merged with and into Veeco (the "Merger"), with Veeco surviving as a wholly-owned subsidiary of Axcelis. The Merger Agreement was approved by our board of directors (except for one (1) independent director who serves on the Axcelis' board of directors as well who recused himself) and, on February 6, 2026, by the stockholders of each company. The completion of the Merger remains subject to the satisfaction or (to the extent permissible) waiver of customary closing conditions, including the final pending regulatory approval from the State Administration for Market Regulation of the People's Republic of China.

For more information regarding the Merger, see Note 10 "Merger" to the accompanying Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

**Business Update**

*Overview*

Sales in the Semiconductor industry are estimated to have increased year-over-year in 2025 to approximately $770 billion dollars, according to Gartner. Looking ahead, industry analysts are forecasting long-term growth of the industry, driven by secular growth trends such as artificial intelligence, high-performance computing, mobile connectivity, and the electrification of the automotive industry. Additionally, government investments in the Semiconductor industry are projected to accelerate global spending in next-generation technologies.

Growth in the Semiconductor industry, coupled with increasing technological complexity of Semiconductor chips, are expected to drive long-term growth in Wafer Fab Equipment ("WFE") spending. In an effort to improve chip performance, optimize power consumption, and reduce costs, today's most advanced Semiconductor manufacturers are shrinking device geometries, investing in more complex transistor designs such as Gate-All-Around and exploring 3D

[**Table of Contents**](#TOC)

architectures. As a result, growth of the WFE market is forecasted to keep pace with long-term growth of the Semiconductor industry, which we believe should benefit semiconductor capital equipment providers, including Veeco.

Veeco's technologies are at the forefront of enabling new technical innovations in the manufacturing of high-performance AI chips and High-Bandwidth Memory ("HBM"). We continue to invest in new technologies to expand our Serviceable Available Market ("SAM") to a broad range of new applications.

*Semiconductor Market*

Semiconductor revenue comprised 69% of first quarter total revenue primarily driven by system shipments of our Laser Spike Annealing ("LSA"), and our Advanced Packaging, wet processing and lithography products. Semiconductor revenue decreased 12% from the comparable prior period due to a reduction in China revenue of 74% partially offset by increases in Rest of APAC revenue of 38% and United States revenue of 69%.

In the logic market, our annealing solutions continue to gain traction at advanced node customers. Our LSA platform is production tool of record at all three Tier 1 logic customers. Our next-generation Nanosecond Annealing ("NSA") system is progressing through evaluations at Tier 1 logic customers. Our NSA tool addresses critical low-thermal budget applications such as contact annealing, 3D device integration and materials modification. These evaluations are advancing well, and we are anticipating an additional evaluation shipment to a third Tier 1 logic customer in the coming months.

In the memory market, we continue to expand our presence as current and future roadmap requirements for Dynamic-Random-Access Memory ("DRAM") drive the need for low-thermal-budget anneals used in high-band-width memory and vertical DRAM devices. We are the production tool of record at a leading high-bandwidth memory customer, and we continue to make progress with another LSA evaluation system at a second Tier 1 DRAM customer, with potential for pilot line orders in the second half of 2026.

We also have two Ion Beam Deposition "IBD300" systems under evaluation at leading DRAM memory customers. Our IBD300 system provides Veeco with another opportunity to expand our SAM to advanced node applications where low resistance films are critical. These initial systems are being evaluated for advanced memory applications, such as DRAM bitline metallization.

The ongoing adoption of EUV Lithography for advanced node semiconductor manufacturing continues to drive demand for our Ion Beam Deposition EUV system for mask blanks. Leading logic and memory customers expect EUV and High Numerical Aperture ("High-NA") lithography to be integral to their future roadmaps. Our Ion Beam Deposition technology is a key enabler of the EUV mask blank Multiple Layer Mirror deposition. Our product roadmap is well positioned as the industry adopts next-generation High-NA EUV lithography, and we are expanding our EUV related business to EUV pellicles which are increasingly being used to improve the productivity of EUV steps. Our IBD-EUV system is also used to form the high-transparency membrane used in pellicles.

In Advanced Packaging ("AP"), our wet processing systems are used for several applications, and we continue to see strong demand driven by Heterogenous Integration and 2.5D and 3D Packaging for AI and high-performance computing. In the first quarter, we had an increase in orders for our wet processing systems from leading OSAT customers, supporting high-volume manufacturing of next-generation AI accelerators using 2.5D AP architectures.

Looking ahead, we anticipate growth in the semiconductor market in leading-edge investment driven by AI and high-performance computing.

*Compound Semiconductor Market*

Compound Semiconductor revenue increased by 31% in the first quarter from the comparable prior year period, comprising 12% of total revenue. In the Compound Semiconductor market, we have a broad portfolio of products which are gaining momentum due to a significant inflection point within the industry with AI data center infrastructure build-out.

[**Table of Contents**](#TOC)

The AI build-out is impacting interconnects where there is a shift from copper wiring to pluggables and co-packaged optics as data centers demand higher-speed and lower-power communication. Within this space, Indium Phosphide ("InP") lasers are a major component as the light-source for pluggables and co-packaged optics for next-generation AI infrastructure. As the industry transitions toward future capacity requirements, we believe this represents growth opportunity of approximately $2.0 billion dollars over the next several years. Our technology plays a critical role within the manufacturing of InP lasers and order demand is greatly accelerating across multiple of our products. These products include Lumina MOCVD Arsenide Phosphide batch platform, Wafer Etch and Wafer Storm for etching and metal lift-off, and importantly our Spector ion beam deposition for the laser diode facet coatings. Our Spector ion beam deposition system, designed for the critical laser facet coating step, is essential to the process. Veeco is the market leader in ion beam deposition and is highly differentiated from traditional approaches such as E-beam evaporation, ion assisted deposition or physical vapor deposition ("PVD"). Compared with other approaches, the Spector Ion Beam Deposition ("IBD") tool delivers low-loss optical films with tight control of thickness, uniformity, and reflectivity – precision that is required for anti-reflective and high-reflective facet coatings on InP. We received orders over $250 million dollars from multiple customers for our MOCVD, wet processing and ion beam deposition tools to support the manufacturing of InP lasers with deliveries starting in 2026 and significantly accelerating in 2027. A large portion of these orders is from a leading supplier of next-generation 800-gig and 1.6-terabit optical transceivers for hyperscale customers, for our Spector IBD systems. This significant order activity underscores the long-term value of our ion beam deposition technology leadership and our expanding role in this rapidly growing market. We have long-standing partnerships with our customers, spanning more than two decades, and we are well positioned across our multiple differentiated products to meet their growing needs in silicon photonics.

Additionally, there are other photonics applications driving growth for our products in this space, including red MircoLEDs, low earth orbit solar cells and augmented / virtual reality applications.

Lastly, our Propel300mm GaN on Si product continues to be a strong long-term driver tied to AI data center power efficiency, electrification, and high-power density applications. At a leading power IDM customer, we have an evaluation for our Propel300 system in place, and we received a pilot-line order for a multi-chamber system at the end of 2025. As this leading customer ramps and finalizes long-term capacity plans, there is potential for additional system orders in the second half of 2026 for delivery in 2027.

We expect our compound semiconductor market to grow as AI, power efficiency and advanced connectivity continue to reshape the industry.

*Data Storage Market*

Data Storage market revenue increased by 52% in the first quarter from the comparable prior year period, comprising 6% of total revenue. We address the Data Storage market with sales of our Ion Beam technology and wet process systems driven by demand for cloud and AI data centers. We have seen increase in order activity in the back-half of 2025 and increased customer utilization rates as customers gain traction in new technologies like Heat Assisted-Magnetic-Recording ("HAMR"). Orders received in the third and fourth quarter of 2025 for our ion beam and wet processing equipment from demand for cloud and AI data centers, will drive revenue growth in 2026, principally in the second half. Customer engagement remains strong with our business fully booked in 2026 and extending into 2027.

*Scientific & Other Market*

Scientific & Other market revenue decreased by 9% in the first quarter from the comparable prior year period, comprising 13% of total revenue. Sales in the Scientific & Other market are largely driven by sales to government-funded laboratories, universities, and research institutions. We address the Scientific & Other market with several technologies, including MBE, ALD, MOCVD, Wet Processing, and IBD/IBE, which support diverse R&D and niche low-volume production applications.

[**Table of Contents**](#TOC)

**Results of Operations**

**For the three months ended March 31, 2026 and 2025**

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the indicated periods in 2026 and 2025 and the period-over-period dollar and percentage changes for those line items. Our results of operations are reported as one business segment, represented by our single operating segment.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | **Change** | **Change** |
|  | **2026** | **2026** | **2025** | **2025** | **Period to Period** | **Period to Period** |
|  | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* |
| Net sales | $158341 | 100% | $167292 | 100% | $(8951) | (5)% |
| Cost of sales | 102513 | 65% | 98825 | 59% | 3688 | 4% |
| Gross profit | 55828 | 35% | 68467 | 41% | (12639) | (18)% |
| Operating expenses, net: |  |  |  |  |  |  |
| &nbsp;&nbsp;Research and development | 29875 | 19% | 28514 | 17% | 1361 | 5% |
| &nbsp;&nbsp;Selling, general, and administrative | 26016 | 16% | 25028 | 15% | 988 | 4% |
| &nbsp;&nbsp;Amortization of intangible assets | 705 | 0% | 821 | 0% | (116) | (14)% |
| &nbsp;&nbsp;Merger costs | 2012 | 1% |  | 0% | 2012 | \* |
| &nbsp;&nbsp;Other operating expense (income), net | (122) | (0)% | (44) | (0)% | (78) | \* |
| Total operating expenses, net | 58486 | 37% | 54319 | 32% | 4167 | 8% |
| Operating income (loss) | (2658) | (2)% | 14148 | 8% | (16806) | \* |
| &nbsp;&nbsp;Interest income, net | 1175 | 1% | 836 | 0% | 339 | 41% |
| Income (loss) before income taxes | (1483) | (1)% | 14984 | 9% | (16467) | (110)% |
| &nbsp;&nbsp;Income tax expense (benefit) | (1159) | (1)% | 3037 | 2% | (4196) | (138)% |
| Net income (loss) | $(324) | (0)% | $11947 | 7% | $(12271) | (103)% |

---

\* Not meaningful

*Net Sales*

The following is an analysis of sales by market and by region:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | **Change** | **Change** |
|  | **2026** | **2026** | **2025** | **2025** | **Period to Period** | **Period to Period** |
|  | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* | *(dollars in thousands)* |
| **Sales by end-market** |  |  |  |  |  |  |
| &nbsp;&nbsp;Semiconductor | $109042 | 69% | $123823 | 74% | $(14781) | (12)% |
| &nbsp;&nbsp;Compound Semiconductor | 18808 | 12% | 14397 | 9% | 4411 | 31% |
| &nbsp;&nbsp;Data Storage | 10213 | 6% | 6705 | 4% | 3508 | 52% |
| &nbsp;&nbsp;Scientific & Other | 20278 | 13% | 22367 | 13% | (2089) | (9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $158341 | 100% | $167292 | 100% | $(8951) | (5)% |
| **Sales by geographic region** |  |  |  |  |  |  |
| &nbsp;&nbsp;United States | $32225 | 20% | $24062 | 15% | $8163 | 34% |
| &nbsp;&nbsp;EMEA | 15784 | 10% | 12337 | 7% | 3447 | 28% |
| &nbsp;&nbsp;China | 19956 | 13% | 70892 | 42% | (50936) | (72)% |
| &nbsp;&nbsp;Rest of APAC | 90364 | 57% | 59976 | 36% | 30388 | 51% |
| &nbsp;&nbsp;Rest of World | 12 | - | 25 | - | (13) | (52)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | $158341 | 100% | $167292 | 100% | $(8951) | (5)% |

---

Sales decreased for the three months ended March 31, 2026 against the comparable prior year period driven by a decrease in sales in the Semiconductor, and Scientific & Other markets, partially offset by an increase in sales in the

[**Table of Contents**](#TOC)

Compound Semiconductor and Data Storage markets. By geography, sales decreased in the China region, partially offset by increased sales in the Rest of APAC, United States, and EMEA regions. Sales in the Rest of APAC region for the three months ended March 31, 2026 included sales in Taiwan and Japan of $65.6 million and $9.2 million, respectively. Sales in the Rest of APAC region for the three months ended March 31, 2025 included sales in Japan and Taiwan of $32.5 million, and $14.0 million respectively. In light of the global nature of our business, we are impacted by conditions in the various countries in which we and our customers operate, including the recent tariff and trade dynamics. We expect there will continue to be year-to-year variations in our future sales distribution across markets and geographies.

*Gross Profit*

For the three months ended March 31, 2026, gross profit decreased against the comparable prior period primarily due to a decrease in sales volume, as well as a decrease in gross margins. Gross margins decreased principally due to unfavorable product mix and higher logistics costs. Additionally other factors will cause our gross margins to fluctuate each period, including the impact of the evolving tariffs landscape, which may include potential refunds on previously paid tariffs, newly implemented tariffs, or changes to existing tariffs.

*Research and Development*

The markets we serve are characterized by continuous technological development and product innovation, and we invest in various research and development initiatives to maintain our competitive advantage and achieve our growth objectives. Research and development expenses increased for the three months ended March 31, 2026 against the comparable prior period due to an increase in personnel-related expenses.

*Selling, General, and Administrative*

Selling, general, and administrative expenses increased for the three months ended March 31, 2026 against the comparable prior period due to personnel-related expenses.

*Merger Costs*

During the three months ended March 31, 2026, we incurred an additional $2.0 million in legal, accounting, consulting fees and employee-related costs in connection with the proposed Merger.

*Interest Income (Expense)*

We recorded net interest income of $1.2 million for the three months ended March 31, 2026, compared to net interest income of $0.8 million for the comparable prior year period. The increase in net interest income was primarily due to reduced interest expense on the 2025 Notes as they matured on January 15, 2025 and the 2027 Notes that were settled on May 15, 2025.

*Income Taxes*

Our tax benefit for the three months ended March 31, 2026, was $1.2 million, compared to $3.0 million of tax expense for the comparable prior period. For the three months ended March 31, 2026, the effective tax rate was higher than the U.S. statutory tax rate primarily related to a discrete income tax benefit for share-based compensation windfall. For the three months ended March 31, 2025, the effective tax rate was in line with the U.S. statutory tax rate, which included a $1.5 million tax expense related to share-based compensation shortfalls, partially offset by tax benefits related to Foreign-Derived Intangible Income and research and development tax credits.

[**Table of Contents**](#TOC)

**Liquidity and Capital Resources**

Our cash and cash equivalents, restricted cash, and short-term investments are as follows:

---

| | | |
|:---|:---|:---|
|  | **March 31,**  | **December 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Cash and cash equivalents | $179535 | $163466 |
| Short-term investments | 203796 | 226763 |
| &nbsp;&nbsp;**Total** | $383331 | $390229 |

---

At March 31, 2026 and December 31, 2025, cash and cash equivalents of $34.0 million and $23.6 million, respectively, were held outside the United States. As of March 31, 2026, we had $27.5 million of accumulated undistributed earnings generated by our non-U.S. subsidiaries for which the U.S. tax has previously been provided. Approximately $13.4 million of undistributed earnings will be subject to foreign withholding taxes if distributed back to the United States and we accrued $1.4 million for foreign withholding taxes for the undistributed earnings.

We believe that our projected cash flow from operations, combined with our cash and short-term investments, will be sufficient to meet our projected working capital requirements, contractual obligations, and other cash flow needs for the next twelve months, including scheduled principal and interest payments on our convertible senior notes, purchase commitments, and payments required under our operating leases.

A summary of the cash flow activity for the three months ended March 31, 2026 and 2025 is as follows:

*Cash Flows from Operating Activities*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Net income (loss) | $(324) | $11947 |
| Non-cash items: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 5037 | 5035 |
| &nbsp;&nbsp;Non-cash interest expense | 244 | 257 |
| &nbsp;&nbsp;Deferred income taxes | (1088) | 1567 |
| &nbsp;&nbsp;Share-based compensation expense | 8511 | 9208 |
| Changes in operating assets and liabilities | (4445) | (8022) |
| &nbsp;&nbsp;**Net cash provided by (used in) operating activities** | $7935 | $19992 |

---

Net cash provided by operating activities was $7.9 million for the three months ended March 31, 2026 and was due to net loss of $0.3 million and adjustments for non-cash items of $12.7 million, partially offset by a decrease in cash flow from changes in operating assets and liabilities of $4.4 million. The changes in operating assets and liabilities were largely attributable to an increase in accounts receivables, and inventories, partially offset by an increase in contract liabilities, accrued expenses, and accounts payable.

*Cash Flows from Investing Activities*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Capital expenditures | $(5103) | $(6755) |
| Changes in investments, net | 22794 | 21278 |
| &nbsp;&nbsp;**Net cash provided by (used in) investing activities** | $17691 | $14523 |

---

The cash provided by investing activities during the three months ended March 31, 2026 was primarily attributable to net cash provided for investment activity, partially offset by capital expenditures. The cash provided by investing activities

[**Table of Contents**](#TOC)

during the three months ended March 31, 2025 was primarily attributable to net cash used for investment activity, partially offset by capital expenditures.

*Cash Flows from Financing Activities*

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Settlement of equity awards, net of withholding taxes | $(9558) | $(5276) |
| &nbsp;&nbsp;**Net cash provided by (used in) financing activities** | $(9558) | $(5276) |

---

The cash used in financing activities for the three months ended March 31, 2026 was related to cash used to settle taxes related to employee equity programs, offset by cash received under the Employee Stock Purchase Plan. The cash used in financing activities for the three months ended March 31, 2025 was related to cash used to settle taxes related to employee equity programs, partially offset by cash received under the Employee Stock Purchase Plan.

*Convertible Senior Notes*

We have $230.0 million outstanding principal balance of convertible senior notes that bear interest at a rate of 2.875% per year, payable semiannually in arrears on June 1 and December 1 of each year, and mature on June 1, 2029, unless earlier purchased by the Company, redeemed, or converted.

We believe that we have sufficient capital resources and cash flows from operations to support scheduled interest payments on this debt. In addition, in June 2025, we increased the total funds available to us through our revolving credit facility from $225 million to $250 million and extended the maturity until June 16, 2030, subject to a springing maturity date of March 2, 2029. The Company has no immediate plans to draw down on the facility. Interest under the facility is variable based on the Company's secured net leverage ratio and is expected to bear interest based on SOFR plus a range of 125 to 200 basis points, if drawn. There is a yearly commitment fee of 20 to 30 basis points, based on the Company's secured net leverage ratio, charged on the unused portion of the Facility.

In connection with the Merger, the convertible senior notes will be assumed by Axcelis.

*Contractual Obligations and Commitments*

We have commitments under certain contractual arrangements to make future payments for goods and services. These contractual arrangements secure the rights to various assets and services to be used in the future in the normal course of business. We expect to fund these contractual arrangements with cash generated from operations in the normal course of business.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

*Interest Rate Risk*

Our exposure to market rate risk for changes in interest rates primarily relates to our investment portfolio. We centrally manage our investment portfolios considering investment opportunities and risks, tax consequences, and overall financing strategies. Our investment portfolio includes fixed-income securities with a fair value of approximately $203.8 million at March 31, 2026. These securities are subject to interest rate risk and, based on our investment portfolio at March 31, 2026, a 100 basis point increase in interest rates would result in a decrease in the fair value of the portfolio of $1.5 million. While an increase in interest rates may reduce the fair value of the investment portfolio, we will not realize the losses in the Consolidated Statements of Operations unless the individual fixed-income securities are sold prior to recovery or the loss is determined to be other-than-temporary.

[**Table of Contents**](#TOC)

*Currency Exchange Risk*

We conduct business on a worldwide basis and, as such, a portion of our revenues, earnings, and net investments in foreign affiliates is exposed to changes in currency exchange rates. The economic impact of currency exchange rate movements is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions, and other factors. These changes, if material, could cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.

Changes in currency exchange rates could affect our foreign currency denominated monetary assets and liabilities and forecasted cash flows. We may enter into monthly forward derivative contracts from time to time with the intent of mitigating a portion of this risk. We only use derivative financial instruments in the context of hedging and not for speculative purposes and have not historically designated our foreign exchange derivatives as hedges. Accordingly, changes in fair value from these contracts are recorded as "Other, net" in our Consolidated Statements of Operations. We execute derivative transactions with highly rated financial institutions to mitigate counterparty risk.

Our net sales to customers located outside of the United States represented approximately 80% and 86% of our total net sales for the three months ended March 31, 2026 and 2025, respectively. We expect that net sales to customers outside the United States will continue to represent a large percentage of our total net sales. Our sales denominated in currencies other than the U.S. dollar represented approximately 2% and 6% of total net sales for the three months ended March 31, 2026 and 2025, respectively.

A 10% change in foreign exchange rates would have an immaterial impact on the consolidated results of operations since most of our sales outside the United States are denominated in U.S. dollars.

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures*

Our principal executive and financial officers have evaluated and concluded that our disclosure controls and procedures are effective as of March 31, 2026. The disclosure controls and procedures are designed to ensure that the information required to be disclosed in this report filed under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and is accumulated and communicated to our principal executive and financial officers as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control Over Financial Reporting*

During the quarter ended March 31, 2026, there were no changes in internal control that have materially affected or are reasonably likely to materially affect internal control over financial reporting.

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings**

The Company is involved in various legal proceedings arising in the normal course of business. The Company does not believe that the ultimate resolution of these matters will have a material adverse effect on its consolidated financial position, results of operations, or cash flows.

**Item 1A. Risk Factors**

Information regarding risk factors appears in the Safe Harbor Statement at the beginning of this quarterly report on Form 10-Q, in Part I — Item 1A of our 2025 Form 10-K. There have been no material changes from the risk factors previously disclosed.

[**Table of Contents**](#TOC)

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not Applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

Unless otherwise indicated, each of the following exhibits has been filed with the Securities and Exchange Commission by Veeco under File No. 0-16244.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| **Exhibit**<br>**Number** | <br>**Exhibit Description** | **Form** | **Exhibit** | **Filing Date** | **Filed or**<br>**Furnished**<br>**Herewith** |
| 10.1 | [Form of Notice of Restricted Stock Unit Award and related terms and conditions pursuant to the Veeco 2019 Stock Incentive Plan, effective March 2026.](veco-20260331xex10d1.htm) |  |  |  | \* |
| 31.1 | [Certification of Chief Executive Officer pursuant to Rule 13a—14(a) or Rule 15d—14(a) of the Securities and Exchange Act of 1934.](veco-20260331xex31d1.htm) |  |  |  | \* |
| 31.2 | [Certification of Chief Financial Officer pursuant to Rule 13a—14(a) or Rule 15d—14(a) of the Securities and Exchange Act of 1934.](veco-20260331xex31d2.htm) |  |  |  | \* |
| 32.1 | [Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002.](veco-20260331xex32d1.htm) |  |  |  | \* |
| 32.2 | [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002.](veco-20260331xex32d2.htm) |  |  |  | \* |
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  | \*\* |
| 101.XSD | XBRL Schema. |  |  |  | \*\* |
| 101.PRE | XBRL Presentation. |  |  |  | \*\* |
| 101.CAL | XBRL Calculation. |  |  |  | \*\* |
| 101.DEF | XBRL Definition. |  |  |  | \*\* |
| 101.LAB | XBRL Label. |  |  |  | \*\* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |  |  |  | \*\* |

---

\*&nbsp;&nbsp;&nbsp;&nbsp; Filed herewith

\*\* Filed herewith electronically

[**Table of Contents**](#TOC)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 5, 2026.

---

| | |
|:---|:---|
| Veeco Instruments Inc. | Veeco Instruments Inc. |
| By: | /s/ WILLIAM J. MILLER, Ph.D. |
|  | William J. Miller, Ph.D. |
|  | *Chief Executive Officer* |
| By: | /s/ JOHN P. KIERNAN |
|  | John P. Kiernan |
|  | *Senior Vice President and Chief Financial Officer* |

---

## Exhibit 10.1

**Exhibit 10.1**

#### VEECO INSTRUMENTS INC. 2019 STOCK INCENTIVE PLAN<br>NOTICE OF RESTRICTED STOCK UNIT AWARD (2026)
Veeco Instruments Inc. (the "<u>Company</u>") is pleased to confirm the award to the individual named below (the "<u>Grantee</u>") of Restricted Stock Units (the "<u>Award</u>"), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (2026) (the "<u>Notice</u>"), the Veeco Instruments Inc. 2019 Stock Incentive Plan, as amended from time to time (the "<u>Plan</u>") and the Veeco Instruments Inc. Terms and Conditions of Restricted Stock Unit Award (2026) (the "<u>Terms and Conditions</u>") attached hereto, as follows. Unless otherwise defined herein, the terms in this Notice shall have the same meaning as those defined in the Plan.

Grantee:

Award Date: March 10, 2026

Total Number of Restricted Stock<br>Units Awarded (the "<u>Units</u>"):

Subject to the Grantee's Continuous Service and other limitations set forth in this Notice, the Terms and Conditions and the Plan, the Units will "vest" in accordance with the following schedule (the "<u>Vesting Schedule</u>"): 1/3 of the Units comprising the Award will vest, and the restrictions with respect to such shares shall lapse, on each of the first (1<sup>st</sup>), second (2<sup>nd</sup>) and third (3<sup>rd</sup>) anniversaries of the Award Date (or, if later, the date on which the issuance of shares will not cause a violation of United States federal securities laws) (the later of each such dates, a "<u>Vesting Date</u>"). If the Grantee would become vested in a fraction of a share on a Vesting Date, such share shall not vest until the Grantee becomes vested in the entire share on the following Vesting Date.

For purposes of this Notice and the Terms and Conditions, the term "vest" shall mean, with respect to any Units, that such Units are no longer subject to forfeiture to the Company. If the Grantee would become vested in a fraction of a Unit, such Unit shall not vest until the Grantee becomes vested in the entire Unit.

Except as otherwise provided in an agreement with the Grantee or a plan or policy covering the Grantee, including, if applicable to the Grantee, the Company's Amended and Restated Senior Executive Change in Control Policy (as may be amended or superseded, the "<u>CIC Policy</u>"), vesting shall cease upon the date the Grantee's Continuous Service terminates for any reason other than a termination (i) due to the Grantee's death or (ii) by the Company or a Related Entity due to the Grantee's Disability (any such termination described in (i) or (ii) or, if the Grantee is a participant in the CIC Policy, any termination that results in vesting of equity awards under the CIC Policy, a "<u>Qualifying Termination</u>"), and any unvested Units held by the Grantee immediately upon such termination of the Grantee's Continuous Service (other than a Qualifying Termination) shall be forfeited and deemed reconveyed to the Company and the Company shall thereafter be the legal and beneficial owner of such reconveyed Units and shall have all rights and interest in or related thereto without further action by the Grantee. In the event of a Qualifying Termination, the Units shall vest immediately as of the date of the Qualifying Termination.

**IMPORTANT NOTICE**

**Grantee must sign this Notice and return it to the Company's Sr. VP, Chief Administrative Officer on or before April 24, 2026. Return your executed Notice to: Robert Bradshaw by mail at 1 Terminal Drive, Plainview, New York 11803, or email at RBradshaw@Veeco.com** **. If Grantee has received this Notice by way of email from the Company, and if Grantee is unable to sign and return** 

------

**the Notice on or before the aforementioned date, Grantee may accept the Award by reply email to the Company, stating "I accept" (or words to this effect) on or before the aforementioned date.**

------

PLEASE NOTE THAT YOUR acceptance of the Award will also constitute acceptance of, and agreement to be bound by, the Terms and Conditions governing the Award, including without limitation, the Forfeiture for Restricted Activity, Clawback, Governing Law and Venue and Waiver of Jury Trial provisions of Sections 5.5, 5.10, 6.1 and 6.5 of the Terms and Conditions.

VEECO INSTRUMENTS INC.

![Graphic](veco-20260331xex10d1001.jpg)

Name: Robert Bradshaw<br>Title: Sr. VP, Chief Administrative Officer

Grantee

______________________________________________________________

Print Name Signature Date

------

#### VEECO INSTRUMENTS INC. 2019 STOCK INCENTIVE PLAN <br>TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT AWARD<br>(2026)
These TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT AWARD (2026) (these "<u>Terms and Conditions</u>") apply to any award by Veeco Instruments Inc., a Delaware corporation (the "<u>Company</u>"), of Restricted Stock Units, subject to certain restrictions pursuant to the Veeco Instruments Inc. 2019 Stock Incentive Plan (as it may be amended from time to time, the "<u>Plan</u>"), which specifically references these Terms and Conditions.

#### ARTICLE 1 <br>ISSUANCE OF UNITS
The Company hereby issues to the Grantee (the "<u>Grantee</u>") named in the Notice of Restricted Stock Unit Award (2026) (the "<u>Notice</u>") an award (the "<u>Award</u>") of the Total Number of Restricted Stock Units Awarded set forth in the Notice (the "<u>Units</u>"), subject to the Notice, these Terms and Conditions, and the terms and provisions of the Plan, which is incorporated herein by reference. Unless otherwise provided herein, capitalized terms in these Terms and Conditions shall have the same meaning as those defined in the Plan.

#### ARTICLE 2 <br>CONVERSION OF UNITS AND ISSUANCE OF SHARES
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1<u>General</u>. One share of Common Stock shall be issuable for each Unit subject to the Award that vests (the "<u>Shares</u>") and, subject to Section 2.2, as soon as administratively feasible (and, in all events, not more than sity (60) days after the date the Units vest), the Company will transfer the appropriate number of Shares and the related Cash Dividend Equivalents (as defined in Article 3) with respect to such Shares to the Grantee after satisfaction of any required tax or other withholding obligations. Any fractional Unit remaining after the Award is fully vested shall be discarded and shall not be converted into a fractional Share. If a Cash Dividend Equivalent becomes payable with respect to vested Units and the Shares were issued after the dividend record date but before the dividend payment date, the related Cash Dividend Equivalents with respect to such Units shall be provided when the related dividend is paid. The Company may however, in its sole discretion, make a cash payment in lieu of the issuance of the Shares in an amount equal to the value of one share of Common Stock multiplied by the number of Units subject to the Award. The number of Shares covered by the Award shall be proportionately adjusted for any stock dividend affecting the Shares in accordance with Section 10 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2<u>Delay of Issuance of Shares</u>. The Company shall delay the issuance of any Shares and the payment of Cash Dividend Equivalents under this Article 2 to the extent necessary to comply with Section 409A(a)(2)(B)(i) of the Code ("<u>Section 409A</u>") (relating to payments made to certain "specified employees" of certain publicly-traded companies); in such event, any Shares and Cash Dividend Equivalents to which the Grantee would otherwise be entitled during the six (6) month period following the date of the Grantee's termination of Continuous Service will be issuable on the first business day following the expiration of such six (6) month period.

#### ARTICLE 3

#### RIGHT TO SHARE S
Except as set forth herein, the Grantee shall not have any right in, to or with respect to any of the Shares (including any voting rights) issuable under the Award until the Award is settled by the issuance of

------

such Shares to the Grantee. Notwithstanding the foregoing, while one or more Shares remain subject to this Award, the Grantee shall have the right to accrue Cash Dividend Equivalents (as defined in this Article 3). For purposes of this Agreement, a "<u>Cash Dividend Equivalent</u>" means, for each Share subject to the Award, a cash payment equal to the cash dividend, if any, that would have become payable to the Grantee with respect to such Share had the Grantee been the holder of such Share. Cash Dividend Equivalents that have accrued will vest and become payable upon the same terms and at the same time as the Units to which they relate, except as otherwise provided herein.

#### ARTICLE 4 <br>TAXES
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1<u>Tax Liability</u>. The Grantee is ultimately liable and responsible for all taxes owed by the Grantee in connection with the Award, regardless of any action the Company or any Related Entity takes with respect to any tax withholding obligations that arise in connection with the Award. Neither the Company nor any Related Entity makes any representation or undertaking regarding the treatment of any tax withholding in connection with any aspect of the Award, including the grant, vesting, assignment, release or cancellation of the Units, the delivery of Shares, the payment of any Cash Dividend Equivalents, the subsequent sale of any Shares acquired upon vesting and the receipt of any dividends or dividend equivalents. The Company does not commit and is under no obligation to structure the Award to reduce or eliminate the Grantee's tax liability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2<u>Payment of Withholding Taxes</u>. Prior to any event in connection with the Award (e.g., vesting) that the Company determines may result in any tax withholding obligation, whether United States federal, state, local or non-U.S., including any social insurance, employment tax, payment on account or other tax-related obligation (the "<u>Tax Withholding Obligation</u>"), the Grantee must arrange for the satisfaction of the minimum amount of such Tax Withholding Obligation in a manner acceptable to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*By Share Withholding.* If permissible under Applicable Law, the Grantee authorizes the Company to, upon the exercise of its sole discretion, withhold from those Shares otherwise issuable to the Grantee the whole number of Shares sufficient to satisfy the minimum applicable Tax Withholding Obligation with respect to the Shares. The Grantee acknowledges that the withheld Shares may not be sufficient to satisfy the Grantee's minimum Tax Withholding Obligation. Accordingly, the Grantee agrees to pay to the Company or any Related Entity as soon as practicable, including through additional payroll withholding, any amount of the Tax Withholding Obligation that is not satisfied by the withholding of Shares described above. Share withholding may not be used to satisfy the Tax Withholding Obligation with respect to Cash Dividend Equivalents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*By Sale of Shares*. Unless the Grantee determines to satisfy the Tax Withholding Obligation by some other means in accordance with clause (iii) below, the Grantee's acceptance of this Award constitutes the Grantee's instruction and authorization to the Company and any brokerage firm determined acceptable to the Company for such purpose to, upon the exercise of Company's sole discretion, sell on the Grantee's behalf a whole number of Shares from those Shares issuable to the Grantee as the Company determines to be appropriate to generate cash proceeds sufficient to satisfy the minimum applicable Tax Withholding Obligation. Such Shares will be sold on the day such Tax Withholding Obligation arises (e.g., a vesting date) or as soon thereafter as practicable. The Grantee will be responsible for all broker's fees and other costs of sale, and the Grantee agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale. To the extent the proceeds of such sale exceed the Grantee's minimum Tax Withholding Obligation, the Company agrees to pay such excess in cash to the Grantee. The Grantee acknowledges that the Company or its designee is under no

------

obligation to arrange for such sale at any particular price, and that the proceeds of any such sale may not be sufficient to satisfy the Grantee's minimum Tax Withholding Obligation. Accordingly, the Grantee agrees to pay to the Company or any Related Entity as soon as practicable, including through additional payroll withholding, any amount of the Tax Withholding Obligation that is not satisfied by the sale of Shares described above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)*By Check, Wire Transfer or Other Means*. At any time not less than five (5) business days (or such fewer number of business days as determined by the Administrator) before any Tax Withholding Obligation arises (e.g., a vesting date), the Grantee may elect to satisfy the Grantee's Tax Withholding Obligation by delivering to the Company an amount that the Company determines is sufficient to satisfy the Tax Withholding Obligation by (x) wire transfer to such account as the Company may direct, (y) delivery of a certified check payable to the Company, or (z) such other means as specified from time to time by the Administrator.

Notwithstanding the foregoing, the Company or a Related Entity also may satisfy any Tax Withholding Obligation by offsetting any amounts (including, but not limited to, vested Cash Dividend Equivalents, salary, bonus and severance payments) payable to the Grantee by the Company and/or a Related Entity. Furthermore, in the event of any determination that the Company has failed to withhold a sum sufficient to pay all withholding taxes due in connection with the Award, the Grantee agrees to pay the Company the amount of such deficiency in cash within five (5) days after receiving a written demand from the Company to do so, whether or not the Grantee is an employee of the Company at that time.

#### ARTICLE 5 <br>RESTRICTIONS
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1<u>Transfer Restrictions</u>. The Units may not be transferred in any manner other than by will or by the laws of descent and distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2<u>Forfeiture</u>. Unless otherwise provided by written agreement between the Company and the Grantee, which may be entered into at any time, including in connection with the termination of Grantee's Continuous Service, any portion of the Award that is not vested at the time Grantee's Continuous Service terminates shall thereupon be forfeited immediately and without any further action by the Company or the Grantee. The Grantee also may be required to forfeit shares of Restricted Stock subject to the Award, including Shares received pursuant to the Award, in accordance with Section 5.5 below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3<u>Vesting and Lapse of Restrictions</u>. Subject to the Notice, the Plan and these Terms and Conditions (including, for clarity, Sections 5.5 through 5.9), the exposure to the risk of forfeiture set forth in Section 5.2 shall lapse on the Vesting Dates set forth in the Notice. If Grantee would become vested in a fraction of a share on a Vesting Date, such share shall not vest until Grantee becomes vested in the entire share on the following Vesting Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.4<u>Legend</u>. Until such time as the Award has vested and the exposure to forfeiture of the Shares received pursuant to the Award set forth in Section 5.5 and Sections 5.6 through 5.9 (the "<u>Restrictions</u>") have lapsed, the Company may instruct the transfer agent for the Shares and/or other record-keepers to include a restrictive code or similar notation in its records (or legend on stock certificates, if any) to denote the Restrictions and any applicable federal and/or state securities laws restrictions relating to Restricted Stock. The notation or legend may include the following:

"THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS SET FORTH IN THE PLAN AND IN THE TERMS AND CONDITIONS APPLICABLE TO THE RESTRICTED STOCK AWARD, COPIES

------

OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE CORPORATION."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.5<u>Forfeiture for Restricted Activity</u>. The Grantee acknowledges that the Company is making this Award of additional compensation, among other reasons, to provide an incentive to the Grantee to remain with and to promote the best interests of, the Company, and to protect the Company's assets, including its goodwill, Confidential Information (as defined below) and trade secrets, which are legitimate business interests of the Company, and that engaging in restricted activities described in Sections 5.6 through 5.9 (the "<u>Restricted Activities</u>") would be detrimental to the legitimate business interests of the Company. Therefore, in exchange for this Award, notwithstanding anything to the contrary in these Terms and Conditions or otherwise, if the Grantee engages in Restricted Activities, (a) all unvested portions of the Award will immediately be forfeited, and (b) the Grantee shall be required to (i) return to the Company, within 10 business days after the Company's request to the Grantee therefor, all Shares received pursuant to the Award that are owned, directly or indirectly, by the Grantee and (ii) pay to the Company, within 10 business days of the Company's request to the Grantee therefor, an amount equal to the excess, if any, of the aggregate after-tax proceeds (taking into account all amounts of tax that would be recoverable upon a claim of loss for payment of such proceeds in the year of repayment) Grantee received upon the sale or other disposition of all Shares received pursuant to the Award (the "<u>After-Tax Proceeds</u>"). The forfeiture for Restricted Activity provisions of this Section 5.5 and Sections 5.6 through 5.9 shall survive and continue to apply beyond settlement of all Awards under the Plan, any termination or expiration of this Award for any reason, and after the provisions of any employment or other agreement between the Company and Grantee have lapsed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.7<u>Third Party Information</u>. The Grantee recognizes that the Company has received and in the future will receive from its customers, suppliers and trading partners their confidential or proprietary information subject to a duty on the Company's part to maintain the confidentiality of such information and to use it only for certain limited purposes. The Grantee agrees to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person or entity or to use it except as

------

necessary in carrying out the Grantee's work for the Company consistent with the Company's agreement with such third party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.8<u>Non-Competition</u>. During employment with the Company and for one year thereafter:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the Grantee will not own, manage, work for or otherwise participate in any business whose products, services or activities compete with the current or currently contemplated products, services or activities of the Company in any state or country in which the Company sells products or conducts business and (x) in which the Grantee was involved or (y) with respect to which the Grantee had access to Confidential Information, in each case, during the 5 years prior to termination, provided, however, that Grantee may own up to 1% of the securities of any such public company (but without otherwise participating in the activities of such enterprise); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Grantee will not, for himself or any other person: (i) induce or try to induce any customer, supplier, licensor or business relation to stop doing business with the Company or otherwise interfere with the relationship between the Company and any of its customers, suppliers, licensors or business relations; or (ii) solicit the business of any person known by the Grantee to be a customer of the Company, whether or not the Grantee had personal contact with such person, with respect to products or activities that compete with the products or activities of the Company in existence or contemplated at the time of termination of the Grantee's Continuous Service. The Grantee agrees that this covenant is reasonable with respect to its scope, geographical area, and duration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.9<u>Non-Solicitation</u>. During employment with the Company and for one year thereafter, the Grantee will not, for himself or any other person:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)induce or try to induce any employee to leave the Company or otherwise interfere with the relationship between the Company and any of its employees; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) employ or engage as an independent contractor, any current or former employee of the Company, other than former employees who have not worked for the Company within the past year. The Grantee agrees that this covenant is reasonable with respect to its scope and duration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.10<u>Clawback</u>. This Award and all shares of Common Stock received pursuant to the Award that are owned, directly or indirectly, by the Grantee and any After-Tax Proceeds shall be subject to the Compensation Recoupment Policy, established by the Company, as amended from time to time, or any similar or successor policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.11<u>Notice of Immunity under the Defend Trade Secrets Act and Other Protected Rights</u>. <u>The</u> Grantee understands that, in accordance with the Defend Trade Secrets Act of 2016, the Grantee will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (a) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. The Grantee also understands that if Grantee ever files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Grantee may disclose trade secrets to the Grantee's attorney and use the trade secret information in the court proceeding provided Grantee: (a) files any document containing the trade secret under seal; and (b) does not disclose the trade secret, except pursuant to court order. The Grantee understands that nothing contained in the Notice, these Terms and Conditions, or the Plan limits the Grantee's ability to file a charge or complaint with the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental

------

agency or commission ("<u>Government Agencies</u>"). The Grantee further understands that nothing in the Notice, these Terms and Conditions, or the Plan limits Grantee's ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. Nothing in the Notice, these Terms and Conditions, or the Plan limits the Grantee's right to receive an award for information provided to any Government Agencies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.12<u>Restricted Activity</u>. For the avoidance of doubt, the Company and Grantee agree that the Grantee is free to engage in the activities described in Sections 5.6 through 5.9 and that the Company will not seek to enjoin or otherwise stop the Grantee from engaging in any such Restricted Activities (provided, however, that the Company reserves such right as it may exist at law or in equity and/or pursuant to any other agreement entered into between the Company and the Grantee, including, without limitation, in the ECIA), but that if the Grantee engages in such activities the Company shall have all of the rights set forth in Section 5.5 with respect to the Award, all Shares received pursuant to the Award, and any After-Tax Proceeds.

#### ARTICLE 6

#### OTHER PROVISIONS
**ARTICLE 1**<u>Entire Agreement; Governing Law</u>. The Notice, the Plan and these Terms and Conditions constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee's interest except by means of a writing signed by the Company and the Grantee. For the avoidance of doubt, the restrictions set forth in Sections 5.6 through 5.9 above do not supersede any other agreement between the Company and Grantee, including, without limitation, the ECIA. Nothing in the Notice, the Plan and these Terms and Conditions (except as expressly provided therein) is intended to confer any rights or remedies on any persons other than the parties. Should any provision of the Notice, the Plan or these Terms and Conditions be determined to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed by law and the other provisions shall nevertheless remain effective and shall remain enforceable. The Notice, the Plan and these Terms and Conditions are to be construed in accordance with and governed by the internal laws of the State of New York without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of New York to the rights and duties of the parties. Should any provision of the Notice or these Terms and Conditions be determined to be illegal or unenforceable, the other provisions shall nevertheless remain effective and shall remain enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2<u>Construction</u>. The captions used in the Notice and these Terms and Conditions are inserted for convenience and shall not be deemed a part of the Award for construction or interpretation. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term "or" is not intended to be exclusive, unless the context clearly requires otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3<u>Administration and Interpretation</u>. Any question or dispute regarding the administration or interpretation of the Notice, the Plan or these Terms and Conditions shall be submitted by the Grantee or by the Company to the Administrator. The resolution of such question or dispute by the Administrator shall be final and binding on all persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4<u>Severability</u>. The invalidity or unenforceability of any paragraph or provision (or any part thereof) of the Notice or these Terms and Conditions shall not affect the validity or enforceability of any one or more of the other paragraphs or provisions (or other parts thereof), and all other provisions shall

------

remain in full force and effect. If any provision of the Notice or these Terms and Conditions is held to be excessively broad, then such provision shall be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5<u>Venue and Waiver of Jury Trial</u>. The parties agree that any suit, action, or proceeding arising out of or relating to the Notice, the Plan or these Terms and Conditions shall be brought exclusively in the United States District Court for the Eastern District of New York (or should such court lack jurisdiction to hear such action, suit or proceeding, in a New York state court in the County of Nassau) and that the parties shall submit to the jurisdiction of such court. The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court. THE PARTIES ALSO EXPRESSLY WAIVE ANY RIGHT THEY HAVE OR MAY HAVE TO A JURY TRIAL OF ANY SUCH SUIT, ACTION OR PROCEEDING. If any one or more provisions of this Section 6.5 shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6<u>Notices</u>. Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its address as shown in these instruments, or to such other address as such party may designate in writing from time to time to the other party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.7<u>Conformity to Securities Laws</u>. Grantee acknowledges that the Plan and these Terms and Conditions are intended to conform to the extent necessary with all provisions of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), and any and all regulations and rules promulgated thereunder by the Securities and Exchange Commission, including without limitation Rule 16b-3 under the Exchange Act. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Award is granted, only in such a manner as to conform to such laws, rules and regulations. To the extent permitted by applicable law, the Plan and these Terms and Conditions shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.8<u>Nature of Award</u>. In accepting the Award, the Grantee acknowledges and agrees that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)the Plan is established voluntarily by the Company, it is discretionary in nature, and it may be modified, amended, suspended or terminated by the Company at any time, unless otherwise provided in the Plan and these Terms and Conditions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the Award is voluntary and occasional and does not create any contractual or other right to receive future awards of Units, or benefits in lieu of Units, even if Units have been awarded repeatedly in the past;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)all decisions with respect to future awards, if any, will be at the sole discretion of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)the Grantee's participation in the Plan is voluntary;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)the Grantee's participation in the Plan shall not create a right to any employment with the Grantee's employer and shall not interfere with the ability of the Company or the employer to terminate the Grantee's employment relationship, if any, at any time;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)the Award is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company or any Related Entity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)in the event that the Grantee is not an Employee of the Company or any Related Entity, the Award and the Grantee's participation in the Plan will not be interpreted to form an employment or service contract or relationship with the Company or any Related Entity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)the future value of the underlying Shares is unknown and cannot be predicted with certainty;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)in consideration of the Award, no claim or entitlement to compensation or damages shall arise from termination of the Award or diminution in value of the Award or Shares acquired upon vesting of the Award, resulting from termination of the Grantee's Continuous Service by the Company or any Related Entity (for any reason whatsoever and whether or not in breach of local labor laws) and in consideration of the grant of the Award, the Grantee irrevocably releases the Company and any Related Entity from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by signing the Notice, the Grantee shall be deemed irrevocably to have waived his or her right to pursue or seek remedy for any such claim or entitlement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)in the event of termination of the Grantee's Continuous Service (whether or not in breach of local labor laws), the Grantee's right to receive Awards under the Plan and to vest in such Awards, if any, will terminate effective as of the date that the Grantee is no longer providing services and will not be extended by any notice period mandated under local law (*e.g.*, providing services would not include a period of "garden leave" or similar period pursuant to local law); furthermore, in the event of termination of the Grantee's Continuous Service (whether or not in breach of local labor laws), the Administrator shall have the exclusive discretion to determine when the Grantee is no longer providing services for purposes of this Award;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)the Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding the Grantee's participation in the Plan or the Grantee's acquisition or sale of the underlying Shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)the Grantee is hereby advised to consult with the Grantee's own personal tax, legal and financial advisers regarding the Grantee's participation in the Plan before taking any action related to the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.9<u>Certain Provisions Applicable to Grantees Employed at International Locations</u>. The Company will assess its requirements regarding Tax Withholding Obligations and reporting in connection with the Award and any Shares issued pursuant to the Award. These requirements may change from time to time as laws or interpretations change. Regardless of the actions of the Company in this regard, the Grantee hereby acknowledges and agrees that the ultimate liability for any and all Tax Withholding Obligation is and remains his or her responsibility and liability and that the Company makes no representations nor undertakings regarding treatment of any Tax Withholding Obligation in connection with any aspect of the Award and does not commit to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Grantee's liability regarding Tax Withholding Obligations. In the event that the Company has any Tax Withholding Obligation in connection with the Award, the Grantee agrees to make arrangements satisfactory to the Company to satisfy all withholding requirements. The Grantee authorizes the Company to withhold all applicable Tax Withholding Obligations legally due from Grantee

------

from his or her wages or other cash compensation paid him or her by the Company and/or to cause the sale of Shares on Grantee's behalf or reduce the number of Shares delivered to Grantee as contemplated by Section 2.1 above, to satisfy such Tax Withholding Obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.10<u>Data Privacy</u>. The Grantee hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Grantee's personal data as described in the Notice and these Terms and Conditions by and among, as applicable, the Grantee's employer, the Company and any Related Entity for the exclusive purpose of implementing, administering and managing the Grantee's participation in the Plan. The Grantee understands that the Company and the Grantee's employer may hold certain personal information about the Grantee, including, but not limited to, the Grantee's name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Units or any other entitlement to Shares awarded, canceled, vested, unvested or outstanding in the Grantee's favor, for the exclusive purpose of implementing, administering and managing the Plan ("<u>Data</u>"). The Grantee understands that Data will be transferred to any third party assisting the Company with the implementation, administration and management of the Plan. The Grantee understands that the recipients of the Data may be located in the Grantee's country, or elsewhere, and that the recipients' country may have different data privacy laws and protections than the Grantee's country. The Grantee understands that the Grantee may request a list with the names and addresses of any potential recipients of the Data by contacting the Grantee's local human resources representative. The Grantee authorizes the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing the Grantee's participation in the Plan. The Grantee understands that Data will be held only as long as is necessary to implement, administer and manage the Grantee's participation in the Plan. The Grantee understands that the Grantee may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Grantee's local human resources representative. The Grantee understands, however, that refusal or withdrawal of consent may affect the Grantee's ability to participate in the Plan. For more information on the consequences of the Grantee's refusal to consent or withdrawal of consent, the Grantee understands that the Grantee may contact the Grantee's local human resources representative.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.11<u>No Right to Continued Employment</u>. Nothing in the Notice, these Terms and Conditions or the Plan shall confer upon Grantee any right to continue in the service of the Company or any Related Entity or shall interfere with or restrict in any way the rights of the Company or any Related Entity, which are hereby expressly reserved, to discharge Grantee at any time for any reason whatsoever, with or without cause, except as may otherwise be provided by any written agreement entered into by and between the Company and Grantee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.12<u>No Right to Future Awards</u>. Nothing in the Notice, these Terms and Conditions or the Plan shall confer upon Grantee any right with respect to future Awards under the Plan, or any right with respect to any other award under any plan of the Company or any Related Entity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.13<u>Language</u>. If the Grantee has received these Terms and Conditions or any other document related to the Plan translated into a language other than English and if the translated version is different than the English version, the English version will control, unless otherwise prescribed by Applicable Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.14<u>Section 409A</u>. The Award is intended to comply with Section 409A of the Code or, if applicable, an exemption from Section 409A, and the terms governing the Award will be interpreted

------

accordingly. If the terms of any other agreement, plan or policy applicable to the Award woud cause the Award not to comply with Section 409A, such terms shall (a) be modified (to the minimum extent necessary) to avoid such non-complance or (b) if such non-compliance may not be remedied by modification of terms, not apply to the Award. The Grantee acknowledges that the Company, in the exercise of its sole discretion and without the consent of the Grantee, may amend or modify these Terms and Conditions in any manner and delay or otherwise modify the timing of the issuance of any Shares (or cash) issuable pursuant to these Terms and Conditions to the minimum extent necessary to meet the requirements of Section 409A of the Code as amplified by any Treasury regulations or guidance from the Internal Revenue Service as the Company deems appropriate or advisable. In addition, the Company makes no representation that the Award will comply with Section 409A of the Code and makes no undertaking to prevent Section 409A of the Code from applying to the Award or to mitigate its effects on any deferrals or payments made in respect of the Units. The Grantee is encouraged to consult a tax adviser regarding the potential impact of Section 409A of the Code.

\* \* \* \* \*

------

## Exhibit 31.1

**Exhibit 31.1**

CERTIFICATION PURSUANT TO

RULE 13a — 14(a) or RULE 15d — 14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, William J. Miller, Ph.D., certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2026 of Veeco Instruments Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| By: | /s/ WILLIAM J. MILLER, Ph.D. |
|  | William J. Miller, Ph.D. |
|  | Chief Executive Officer |
|  | Veeco Instruments Inc. |
|  | May 5, 2026 |

---

------

## Exhibit 31.2

**Exhibit 31.2**

CERTIFICATION PURSUANT TO

RULE 13a — 14(a) or RULE 15d — 14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

I, John P. Kiernan, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2026 of Veeco Instruments Inc.;

2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| By: | /s/ JOHN P. KIERNAN |
|  | John P. Kiernan |
|  | Senior Vice President and Chief Financial Officer |
|  | Veeco Instruments Inc. |
|  | May 5, 2026 |

---

------

## Exhibit 32.1

**Exhibit 32.1**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Veeco Instruments Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, William J. Miller, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ WILLIAM J. MILLER Ph.D. |
|  | William J. Miller, Ph.D. |
|  | Chief Executive Officer |
|  | Veeco Instruments Inc. |
|  | May 5, 2026 |

---

A signed original of this written statement required by Section 906 has been provided to Veeco Instruments Inc. and will be retained by Veeco Instruments Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------

## Exhibit 32.2

**Exhibit 32.2**

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Veeco Instruments Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John P. Kiernan, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| By: | /s/ JOHN P. KIERNAN |
|  | John P. Kiernan |
|  | Senior Vice President and Chief Financial Officer |
|  | Veeco Instruments Inc. |
|  | May 5, 2026 |

---

A signed original of this written statement required by Section 906 has been provided to Veeco Instruments Inc. and will be retained by Veeco Instruments Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

------